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Chapter 1: Systematic Literature Review 
 
Effort testing in dementia assessment: A systematic review. 
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Abstract 
Background/Aims: Data from cognitive assessment are examined alongside existing 
published normative data which assumes that the examinee has put forth optimal effort. 
Research however suggests that neuropsychologists do not always formally test for effort and 
that this may especially be the case in the context of dementia assessment. This review 
systematically explores the literature which has investigated the use of both purpose-built and 
embedded effort-sensitive indices in dementia, mild cognitive impairment (MCI) and healthy 
control samples. In particular this review seeks to determine which tests of effort (also known 
as Symptom Validity Tests or SVTs) are most sensitive to sub-optimal effort and least sensitive 
to the type of cognitive impairment seen in dementia. Methods: A systematic search of 
databases was conducted to April 2016. There was no start date. Reference lists were hand 
searched. Twenty studies were included for review. The studies were divided into two 
categories according to methodology. One category of studies (n=5) was reviewed using a 
tailored methodological quality rating checklist whilst the remaining studies (n=15) were 
reviewed using the Crowe Critical Appraisal Tool (CCAT). Results: The systematic search 
process identified 20 studies for review. Conclusions: The results of this review suggest that 
SVTs which take a hierarchical approach to effort testing such as the WMT, MSVT and NV-
MSVT are preferable for use with older adults who are under investigation for possible 
dementia. These tests go above and beyond the traditional pass/fail approach of more 
traditional tests of effort since they allow the examiner to analyse the examinee’s profile of 
scores. The methodological limitations and challenges involved in this field of research are 
discussed. 
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Introduction 
 
Cognitive testing is used in many clinical settings, alongside information gathered from 
other sources, to develop a comprehensive understanding of a person’s difficulties. Scores on 
cognitive tests are usually interpreted alongside published normative data which assume that 
the examinee has put forth good effort. The value and accuracy of an assessment therefore 
relies on the quality of the data to be interpreted and, as such, it is of great importance that the 
clinician has evaluated the examinee’s level of effort and motivation during the assessment 
process.  
 
This has led to the creation of both purpose-built tests designed to detect suboptimal 
effort such as the Test of Memory Malingering (TOMM) [1], the Word Memory Test (WMT) 
[2] and the Rey 15-Item Test (RFIT) [3] and those which have been developed from existing 
neuropsychological test batteries such as the Effort Index (IE) [24] and the Effort Scale (ES) 
[25] derived from the Repeatable Battery for the Assessment of Neuropsychological Status 
(RBANS) [4]. Effort tests are also known as symptom validity tests (SVTs). Both terms (effort 
test and SVT) will be used in this review. 
 
It is a recommended practice of contemporary neuropsychology, that tests of effort be 
included as a routine component of neuropsychological assessment [5]. The British 
Psychological Society also holds this stance, as guidance regarding the assessment of effort in 
cognitive functioning in adults issued in 2009, states: ‘cognitive test results are not valid if the 
examinee does not try hard on the tests and effort tests should be given routinely as part of 
clinical assessment of cognitive function’ [6] (p.1).  
 
There also exist published criteria which can aid clinicians in making a judgement about 
an examinee’s level of effort or motivation. One such set of criteria was published in 1999 by 
Slick and colleagues [7] in a landmark paper which encouraged clinicians to apply a 
‘discrepancy method’ to their judgement of poor effort (e.g. attending to inconsistencies 
between test scores and observed behaviours from the same domain).  
 
Despite these recommendations, however, it appears that effort tests are not always 
routinely administered as part of cognitive assessment. A study carried out in 2009 surveyed 
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130 UK neuropsychologists about their practices and beliefs regarding tests of effort and found 
that whilst 59% of respondents working in forensic settings said that they always used a test of 
effort, only 15% of respondents working in other clinical settings said the same. One third of 
the respondents in this study said that there was no need to use a dedicated test of effort because 
non-credible symptoms were evident from the results of other tests and from the client’s 
general presentation during assessment [8]. Research has found, however, that clinicians’ 
subjective evaluation of test validity is often highly inaccurate [9 - 11] and that analysing 
performance on traditional neuropsychological measures alone is an unreliable method of 
detecting invalid or malingered performance [12]. 
 
It may be that clinicians consider effort tests to only be of relevance when there is 
suspicion that an individual is deliberately feigning symptoms and indeed the majority of the 
literature on effort testing focuses on populations in which the deliberate feigning of symptoms 
is thought to be most prevalent, e.g. medico-legal settings and disability payment assessments. 
Nevertheless, literature does exist which examines the validity and reliability of effort testing 
in various clinical groups such as brain injury [13, 14], depression [15], chronic fatigue 
syndrome [16] and conversion and somatoform disorders [17]. 
 
There is, however, a lack of information on how people with varying degrees of mild 
cognitive impairment (MCI) or dementia would be expected to perform on tests of effort as 
individuals with dementia are often excluded from samples used for effort test validation [18]. 
The BPS guidance states that in certain situations ‘careful consideration of the usefulness of 
effort tests is needed’ (including with subjects with possible dementia) [6] (p.8). 
 
It may be that tests of effort are not routinely validated in samples of older adults who 
are under investigation for memory problems because it is thought that they are unlikely to be 
feigning symptoms. Indeed, a study found that as few as 2% of litigants and those seeking other 
forms of compensation alleged dementia [19]. However, effort can be defined as an ‘investment 
in performing at capacity levels’ [5] (p.420) which is a broader view than malingering which 
refers to the deliberate production of false or exaggerated symptoms motivated by external 
incentives. Although deliberately feigning symptoms may be uncommon in older people who 
present at memory clinics, poor effort can nonetheless impact neuropsychological data for 
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many reasons: depression, medication side effects, stress, lack of interest, fatigue, lack of 
comprehension of the utility of the tests or motivation to be in a ‘sick role’ [20].  
 
In order for clinicians to be able to adequately assess the reliability of data resulting 
from cognitive assessment in older adults presenting with memory problems, they must know 
which effort tests are the most suitable for use with this population. 
 
To date there is no systematic review which examines the literature on the use of effort 
testing in dementia assessment. 
 
Systematic review objectives 
This review evaluates the literature on effort testing in dementia assessment with the 
following objectives: 
 
1. Review which effort tests provide the lowest rate of false-positive error in people with 
MCI and dementia. 
2. Examine the relationship between dementia severity and false-positive rates. 
 
Methods 
 
Search Strategy 
The following electronic bibliographic databases were searched: PsycINFO, Cinahl, 
EMBASE, Medline and Psychology and Behavioural Sciences Collection. The search did not 
have a start date limit. The end date was April 2016. The databases were searched using various 
search terms such as “symptom validity test*”, “test* of effort”, “performance validity test*” 
and “dementia” (see Appendix 1.1 for full strategy). Titles and abstracts of studies identified 
were examined to identify those pertaining to effort testing in dementia assessment. Reference 
lists of all included papers were also examined to identify any further relevant studies. 
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All the titles and abstracts of identified papers featuring the use of effort testing in dementia 
assessment were screened against the following criteria: 
Inclusion criteria: 
 Studies investigating the performance of dementia and/or MCI samples on tests of 
effort. 
 
Exclusion Criteria: 
 Studies which did not use an MCI or dementia sample as their primary sample of 
interest (i.e. a dementia or MCI sample was included but was compared against various 
other clinical groups). 
 Studies which solely used a sample of participants asked to simulate MCI or dementia. 
 Single case studies. 
 
Methodological quality 
In order to rate the methodological quality of the studies included in this review, the studies 
were separated into two different categories based on their methodology. The first category 
pertained to papers where a reference standard is used to establish if a diagnosis is present or 
absent in the participants (in this case the diagnosis would be optimal or sub-optimal effort) 
and then results on the index test (the effort test(s) of interest) are compared between the two 
groups. A reference standard is the best available method for establishing the presence or 
absence of a particular diagnosis. To rate the papers included in this first category (n=5), a 
checklist was developed based on the SIGN Methodology Checklist 5 for Studies of Diagnostic 
Accuracy [21] and the Standards for the Reporting of Diagnostic accuracy studies (STARD) 
statement [22]. The quality rating checklist had a maximum score of 28 points (see Appendix 
1.2 for a copy of the checklist).  
 
The second category covers the majority of the papers included in this review (n=15) where 
the researchers have recruited a sample of participants whom they consider not to meet the 
diagnosis (of sub-optimal effort). In these studies the researchers have either excluded 
participants who may have motivation to feign impairment (involvement in litigation/in receipt 
of disability payments) or they have assumed that their sample will exert optimal effort by 
virtue of having a diagnosis of dementia/MCI. To rate the methodological quality of these 
papers, the Crowe Critical Appraisal Tool (CCAT) was used [23]. The CCAT contains 54 
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reporting items in 8 categories and has a maximum score of 40 points (see Appendix 1.3 for a 
copy of the checklist). 
 
All papers were rated by the author. A second rater assessed 50% of the papers to examine 
the inter-rater reliability of the checklists. Across all the checklist items in the quality rating 
tools, there was 86% agreement between raters. Where discrepancies occurred, these were 
resolved through discussion. 
 
Outcome of search process 
A total of 20 papers met the inclusion criteria and are included in this review. Figure 1 is a 
flow diagram illustrating the systematic process of identifying the 20 papers included.  
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Figure 1. Flowchart illustrating the search process. 
 
 
Papers identified through electronic databases search  
(n=188): 
- Cinahl     (n=13) 
- EMBASE   (n=89)  
- MEDLINE   (n=56) 
- Psychology and Behavioural  
Sciences Collection   (n=16) 
- PsycINFO                                  (n=14) 
Titles screened     (n=125) 
Abstracts screened    (n=30) 
Full text articles screened   (n=25) 
Papers meeting inclusion criteria  (n=15) 
Reference lists hand searched  
for additional papers         (n=5)                    
                         
Papers included in systematic review:  (n=20) 
Papers excluded by title  
(n=95) 
 
Duplicates removed  
(n=63) 
 
Papers excluded by abstract 
(n=5) 
 
Excluded according to 
criteria (n=10) 
Reasons for exclusion: 
Dementia not main sample 
of interest (n=6) 
Simulators only (n=1) 
Looked at diagnostic utility 
of WMT for dementia rather 
than effort (n=1) 
Looked at reliability of SVT 
(n=1) 
Used a sample already 
included in another study 
(n=1) 
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Results 
 
In the review, sensitivity (also called the true positive rate) refers to the ability of the 
tests to identify suboptimal effort when suboptimal effort is present. Specificity (also called the 
true negative rate) refers to the ability of the tests to identify optimal effort when optimal effort 
is present. The majority of the studies included in this review involved participants who were 
deemed to be exerting adequate effort due to not being involved in litigation or by virtue of 
having an established diagnosis of MCI or dementia and therefore having little to no reason to 
feign impairment (n=15). This means that the methodology involved administering tests of 
effort to participants who were already deemed to be exerting optimal effort. These studies 
cannot possibly investigate the sensitivity levels of the effort test(s) in question (there are no 
true positives present in their samples). They report specificity levels only. 
 
The studies (n=5) which include both participants who are and are not exerting adequate 
effort are able to report both sensitivity and specificity levels with the exception of Schroeder 
et al. [46] who used the RBANS Effort Scale as a reference standard but who deemed all of 
their participants to be exerting optimal effort therefore they report specificity levels only. See 
Table 1 for the data extraction table which includes demographic information and sensitivity 
and specificity levels where appropriate. This information is listed per SVT. 
 
The majority of the studies included in this review therefore report specificity levels 
but not sensitivity levels. 
 
The results of the studies included in this review will be reported by effort test: 
1. Test of Memory Malingering (TOMM) [1]. 
2. Repeatable Battery for the Assessment of Neurological Status: 
a. Effort Index (EI) [24]. 
b. Effort Scale (ES) [25]. 
c. Two novel indices (PVI and CRIER) [26]. 
3. Effort tests using profile analysis: 
a. Word Memory Test (WMT) [2, 14]. 
b. Medical Symptom Validity Test ((MSVT) [27]. 
c. Non-Verbal Symptom Validity Test (NV-MSVT) [28]. 
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4. Rey 15 Item Test (RFIT) [3, 29]. 
5. The Coin in the Hand (CIH) [30]. 
6. Reliable Digit Span (RDS) [31]. 
7. Amsterdam Short Memory Test (AMST) [32]. 
8. Dot Counting Test (DCT) [33]. 
 
Please note that the study by Dean et al. [18] included in this review investigated a total of 
18 stand-alone and embedded effort tests. It was out with the scope of this review to include 
all of these SVTs however those which have also been investigated by other studies have been 
included. These are: TOMM, RFIT, DCT and RDS.
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Table 1. Data extraction table per effort test for studies which investigated the diagnostic utility of effort tests in dementia and/or MCI samples. 
1. Test of Memory Malingering (TOMM) [1] – all results refer to a TOMM cut-off of <45/50 on Trial 2. 
Study Sample (n) Age (SD) Education 
(SD) 
Impairment 
measure 
Impairment 
level 
±Sensitivity 
(%) 
*Specificity 
(%) 
Quality 
Rating 
score  
Walter et al., (2014) [34] Dementia (mod/sev) (31) 69.48 (7.86) 15.63 (2.92) RBANS total 
score 
60.7 (7.48) n/a 79 31/40 
(78%) 
MCI (28) 66.02 (8.02) 14.68 (2.09) 80.72 (4.47) n/a 91 
Controls (30) 71.43 (8.99) 16.33 (3.19) 96.73 (8.61) n/a 100 
Bortnik et al., (2013) [35] Good effort (119) 77 (7) 11.42 (4) MMSE 20.8 (5) n/a 78 20/28 
(71%) 
Suspect effort (9) 72 (8.13) 10.44 (2.3) 17.9 (4.5) 100 n/a 
Rudman et al., (2011) [36] Dementia (mild) (20) 58.3 Not reported CAMCOG 88.60 (5.03) n/a 95 28/40 
(70%) 
Dementia (mod/sev) (22) 62.45 (16.21) n/a 36 
Dean et al., (2009) [18] Dementia (20) Not reported Not reported MMSE 19.2 (4.4) n/a 45 30/40 
(75%) 
Merten et al., (2007) [37] AD dementia (20) 73.5 (4.8) 11.7 (3.3) MMSE 22.2 (2.9) n/a 70 30/40 
(75%) 
Controls (14) 76.6 (6.7) 11.3 (3.7) 28.9 (1.0) n/a 100 
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Teichner & Wagner., (2004) [38] Dementia (21) 75.3 (6.1) 13.6 (3.3) MMSE 
WAIS FSIQ 
19.9 (2.8) 
MMSE 
80.6 (12) 
WAIS 
n/a 24 27/40 
(68%) 
MCI (36) 70.6 (8.1) 14.2 (3.2) 25.6 (2.5) 
MMSE 
90.8 (14.8) 
WAIS 
n/a 91.7 
Controls (21) 65.6 (8.6) 14.2 (3.6) 28.3 (1.7) 
MMSE 
99.1 (15.3) 
WAIS 
n/a 100 
Tombaugh et al., (1997) [1] Dementia (37) 69.48 (7.86) 72.1 (7.6) MMSE Not reported n/a 72.9 30/40 
(75%) 
Controls (13) 66.02 (8.02) 45.9 (15) 
*Specificity means that the test correctly identified optimal effort (i.e. the proportion of true negatives). 
±Sensitivity means that the test correctly identified sub-optimal effort (i.e. the proportion of true positives).    
RBANS  = Repeatable Battery for the Assessment of Neuropsychological Status                                                                                                                                                                                                                                          
MMSE = Mini-Mental State Examination                                                                                                                                                                                                                                   
CAMCOG = Cambridge Cognitive Examination                                                                                                                                                                                                                                    
WAIS FSIQ = Wechsler Adult Intelligence Scale, Full Scale Intelligence Quotient                                                         
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2a. RBANS Effort Index (EI) [24] – all results refer to a cut-off of >3. 
Study Sample (n) Age (SD) Education 
(SD) 
Impairment 
measure 
Impairment level 
(mean) 
±Sensitivity 
(%) 
*Specificity (%) Quality Rating score  
Paulson et al., (2015) 
[26] 
Valid responding (189) 69.2 (9.4) 12.9 (3.2) MMSE 
 
RBANS Total 
scores 
27.5 (2.2) MMSE 
85 (12.2) RBANS 
n/a 63 27/28 (96%) 
Invalid responding (45) 64.2 
(10.9) 
12.3 (2.9) 23.1 (4.9) MMSE 
59.9 (10.7) 
RBANS 
93 n/a 
Burton et al., (2015) 
[39] 
AD dementia (90) Not 
reported 
Not reported CDR Not reported n/a 51 27/40 (68%) 
Non-AD dementia (55) n/a 54 
Dunham et al., (2014) 
[40] 
Memory impairment 
(dementias) (46) 
76.44 
(10.49) 
11.17 (2.82) RBANS Total 
scores 
57.48 (11.70) n/a 41 20/28 (71%) 
aSimulators (44) 27.82 
(9.01) 
16.41 (0.82) 48.52 (8.66) 89 n/a 
Bortnik et al., (2013) 
[35] 
Good effort (119) 77 (7) 11.42 (4) MMSE 20.8 (5) n/a 69.6 20/28 (71%) 
Suspect effort (9) 72 (8.13) 10.44 (2.3) 17.9 (4.5) 50 n/a 
Novitski et al., (2012) 
[25] 
aMCI (15) 80.61 
(6.33) 
Not reported RBANS total 
scores 
64.58 (12.89) n/a Not reported 
(AUC 0.608) 
21/40 (53%) 
probable AD (54) n/a Not reported 
Controls (540) n/a Not reported 
Duff et al., (2011) [41] AD (126) 76.7 (6.8) <9yrs=12 
9-11yrs=14 
RBANS Total 
scores 
65.9 (5.9) n/a 67.1 31/40 (78%) 
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12yrs= 38 
13-15yrs=10 
>15yrs=26 
aMCI (72) 72 (82.1) <9yrs=0 
9-11yrs=3 
12yrs=17 
13-15yrs=23 
>15yrs=57 
92.3 (9.1) n/a 100 
Controls (796) 73.4 (5.9) <9yrs=5 
9-11yrs=11 
12yrs=26 
13-15yrs=30 
>15yrs=28 
95.7 (13.3) n/a 97.1 
Barker et al. (2010) [20] Suspect effort (45) 67.1 
(10.3) 
12 (3) RBANS total 
index scores 
IM 57 (16.4) 
DM 51.6 (14.7) 
A 60.7 (15.6) 
L 72 (20.6) 
VS 70.7 (20.9) 
n/a 42.2 22/28 (79%) 
Probable good effort 
(258) 
72.5 (8.8) 12.5 (3.5) IM 75.1 (15.8) 
DM 76 (19.9) 
A 81.9 (16.1) 
L 88.3 (10.6) 
VS 84.3 (17.7) 
95.3 n/a 
*Specificity means that the test correctly identified optimal effort (i.e. the proportion of true negatives).  
±Sensitivity means that the test correctly identified sub-optimal effort (i.e. the proportion of true positives).  
 
MMSE = Mini-Mental State Examination   RBANS = Repeatable Battery for the Assessment of Neuropsychological Status        CDR = Clinical Dementia Rating                                                     
aMCI = amnestic MCI     IM = Immediate Memory   DM = Delayed Memory   A = Attention    L = Language   VS – Visuospatial                                
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b. RBANS Effort Scale (ES) [25] – all results refer to a cut-off of <12. 
Study Sample (n) Age Education Impairment 
measure 
Impairment 
level (mean) 
±Sensitivity 
(%) 
*Specificity 
(%) 
Quality Rating score  
Paulson et al., (2015) [26] Valid 
responding 
(189) 
69.2 (9.4) 12.9 (3.2) MMSE 
RBANS Total 
scores 
27.5 (2.2) 
MMSE 
85 (12.2) 
RBANS 
n/a 42 27/28 (96%) 
Invalid 
responding (45) 
64.2 (10.9) 12.3 (2.9) 23.1 (4.9) 
MMSE 
59.9 (10.7) 
RBANS 
71 n/a 
Burton et al., (2015) [39] AD dementia 
(53) 
Not reported Not reported CDR Not reported n/a 96 
 
69 
27/40 (68%) 
Non-AD 
dementia (36) 
n/a 
Dunham et al., (2014) [40] Memory 
impairment 
(dementias) 
(46) 
76.44 (10.49) 11.17 (2.82) RBANS Total 
scores 
57.48 (11.70) n/a 81 20/28 (71%) 
aSimulators 
(44) 
27.82 (9.01) 16.41 (0.82) 48.52 (8.66) 88 n/a 
Novitski et al., (2012) [25] aMCI (15) 80.61 (6.33) Not reported RBANS total 
scores 
64.58 (12.89) n/a Not reported 
(AUC 0.908) 
21/40 (53%) 
probable AD 
(54) 
Not reported 
Controls (540) 84.9 
*Specificity means that the test correctly identified optimal effort (i.e. the proportion of true negatives). MMSE = Mini–Mental State Examination   CDR = Clinical Dementia Rating 
±Sensitivity means that the test correctly identified sub-optimal effort (i.e. the proportion of true positives).  RBANS = Repeatable Battery for the Assessment of Neuropsychological Status    
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3a. Word Memory Test (WMT) [2, 48]. 
Study Sample (n) Age (SD) Education 
(SD) 
Impairment 
measure 
Impairment 
level 
%Failed 
easy subtests 
(met 
Criterion A) 
% Produced 
dementia 
profile (met 
Criterion A 
not Criterion 
B) 
*Specificity 
(%) 
Quality Rating score 
Green et al., (2011) 
[42] 
Dementia 
group 1 (42) 
70.9 (8) Not reported CDR 1.05 (0.6) 71 100 100 28/40 (70%) 
Dementia 
group 2 (23) 
65.2 (8) 0.83 (0.35) 48 100 100 
MCI (60) 68.8 (8.9) 0.5 single 
domain (29) 
0.5 multi 
domain (31) 
21.6 96.7 96.7 
Controls (19) 55.8 (7.5) 0 0 n/a 100 
**Merten et al., 
(2007) [37] 
AD dementia 
(20) 
73.5 (4.8) 11.7 (3.3) MMSE 22.2 (2.9) **50 n/a **50 30/40 (75%) 
Controls (14) 76.6 (6.7) 11.3 (3.7) 28.9 (1.0) **100 **0 
*Specificity means that the test correctly identified optimal effort (i.e. the proportion of true negatives).             **Based on subtests passed/failed – profile analysis not used.        
 CDR = Clinical Dementia Rating   MMSE = Mini-Mental State Examination                                                                                                                                   
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b. Medical Symptom Validity Test (MSVT) [27]. 
Study Sample (n) Age (SD) Education 
(SD) 
Impairment 
measure 
Impairment 
level 
%Failed 
easy 
subtests 
(met 
Criterion 
A) 
% Produce 
dementia 
profile 
(met 
Criterion 
A not 
Criterion 
B) 
±Sensitivity 
(%) 
*Specificity 
(%) 
Quality Rating 
score 
Green et al., 
(2011) [42] 
Dementia group 
1 (42) 
70.9 (8) Not 
reported 
CDR 1.05 (0.6) Not 
reported 
Not 
reported 
Not reported Not 
reported 
28/40 (70%) 
Dementia group 
2 (23) 
65.2 (8) 0.83 (0.35) 44 100 n/a 100 
MCI (60) 68.8 (8.9) 0.5 single 
domain (29) 
0.5 multi 
domain (31) 
Not 
reported 
Not 
reported 
n/a Not reported 
Controls (19) 55.8 (7.5) 0 Not 
reported 
Not 
reported 
n/a Not reported 
**Rudman et 
al., (2011) [36] 
Dementia (mild) 
(20) 
58.3 Not 
reported 
CAMCOG 88.60 (5.03) 35 Not 
analysed 
n/a *65 28/40 (70%) 
Dementia 
(mod/sev) (22) 
62.45 (16.21) 72 n/a *28 
Singhal et al., 
(2009) [43] 
Institutionalised 
dementia 
patients (10) 
81.7 (4.6) 10 (2.9) MMSE 15.5 (5.3) 100 100 n/a 100 31/40 (78%) 
aSimulators (10) 36 (10) 17 (2) n/a 100 40 60 n/a 
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Howe et al., 
(2007) [44] 
Disability:   WAIS-III 
FSIQ 
FSIQ     35/40 (88%) 
Dementia (5) 56.60 
(4.95) 
11.60 
(2.30) 
82.20 (5.63) 60 100 n/a 100 
MCI (3) 44.33 
(19.50) 
13.33 
(2.31) 
89.33 (5.63) 66.7 0 100 n/a 
Controls (1) 58 13 102 0 n/a n/a n/a 
No Disability        FSIQ 
Dementia early 
(13) 
73.54 
(9.03) 
12 (2.42) 89.27 (14.54) 38.46 80 n/a 80 
Dementia 
advanced (18) 
76.39 
(6.89) 
13.83 (2.92) 86.77 (13.45) 83.33 86 n/a 86 
MCI (16) 69.50 
(9.60) 
15.75 (2.93) 100.94 (10.34) 12.5 100 n/a 100 
Controls (5) 57.20 
(17.33) 
15.40 (1.67) 107.80 (10.26) 0 n/a n/a n/a 
*Specificity means that the test correctly identified optimal effort (i.e. the proportion of true negatives).  
±Sensitivity means that the test correctly identified sub-optimal effort (i.e. the proportion of true positives).  
**Based on subtests passed/failed – profile analysis not used.             
 
CDR = Clinical Dementia Rating   CAMCOG = Cambridge Cognitive Examination   MMSE = Mini-Mental State Examination   WAIS FSIQ = Wechsler Adult Intelligence Scale, Full 
Scale Intelligence Quotient                                                                                               
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c. Non-verbal Medical Symptom Validity Test (NV-MSVT) [28]. 
 
 
Study Sample (n) Age 
(SD) 
Education 
(SD) 
Impairment 
measure 
Impairment 
level 
%Failed easy 
subtests (met 
Criterion A) 
% Produced 
dementia 
profile (met 
Criterion A not 
Criterion B) 
±Sensitivity 
(%) 
*Specificity 
(%) 
Quality Rating 
score 
**Rudman et al., 
(2011) [36] 
Dementia (mild) 
(20) 
58.3 
 
Not 
reported 
CAMCOG 88.60 (5.03) 35 Not analysed n/a **65 28/40 (70%) 
Dementia 
(mod/sev) (22) 
62.45 
(16.21) 
72 n/a **28 
Henry et al., 
(2010) [45] 
Dementia (21) 
Without 
dementia (n=44) 
59.1 
(16.1) 
13.1 (3.4) MMSE 25.7 (3.9) 61 
15 
61 
15 
n/a 100 
97.7 
28/40 (70%) 
Healthy controls 
(50) 
62.8 
(7.1) 
15.8 (3) 28.7 (1.1) 2 2 100 
Singhal et al., 
(2009) [43] 
Institutionalised 
dementia 
patients (10) 
81.7 
(4.6) 
10 (2.9) MMSE 15.5 (5.3) 100 100 n/a 100 31/40 (78%) 
a Simulators 
(10) 
36 
(10) 
17 (2) n/a 90 40 60 n/a 
*Specificity means that the test correctly identified optimal effort (i.e. the proportion of true negatives). 
±Sensitivity means that the test correctly identified sub-optimal effort (i.e. the proportion of true positives). 
**Based on subtests passed/failed – profile analysis not used. 
a Asked to simulate memory impairment. 
 
CAMCOG = Cambridge Cognitive Examination   MMSE = Mini-Mental State Examination    
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4. Rey 15 Item Test (RFIT) [3, 29] – Bortnik et al. [35] use a cut-off of <9, Rudman et al. [36] use a cut-off of <8. 
Study Sample (n) Age (SD) Education 
(SD) 
Impairment 
measure 
Impairment 
level 
±Sensitivity 
(%) 
*Specificity 
(%) 
Quality Rating score  
Bortnik et al., (2013) [35] Good effort 
(119) 
77 (7) 11.42 (4) MMSE 20.8 (5) n/a 28 20/28 (71%) 
Suspect effort 
(9) 
72 (8.13) 10.44 (2.3) 17.9 (4.5) 100 n/a 
Rudman et al., (2011) [36] Dementia 
(mild) (20) 
58.3 Not reported CAMCOG Not reported n/a 85 28/40 (70%) 
Dementia 
(mod/sev) (22) 
n/a 27 
*Specificity means that the test correctly identified optimal effort (i.e. the proportion of true negatives). 
±Sensitivity means that the test correctly identified sub-optimal effort (i.e. the proportion of true positives). 
 
MMSE = Mini-Mental State Examination   CAMCOG = Cambridge Cognitive Examination    
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5. Coin in the Hand (CIH) [30] – all studies used a cut-off of ≤7/10. 
Study Sample (n) Age 
(SD) 
Education 
(SD) 
Impairment 
measure 
Impairment 
level 
 *Specificity (%) Quality Rating score (CCAT) 
Schroeder et al., (2012) [46] Dementia (45) 77.98 
(7.05) 
12.76 
(3.02) 
MMSE 21.47 (5.71) 98 31/40 (78%) 
Rudman et al., (2011) [36] Dementia (mild) (20) 58.3 Not 
reported 
CAMCOG 88.60 (5.03) 100 
 
28/40 (70%) 
Dementia (mod/sev) (22) 62.45 (16.21) 77 
*Specificity means that the test correctly identified optimal effort (i.e. the proportion of true negatives). 
 
MMSE = Mini-Mental State Examination   CAMCOG = Cambridge Cognitive Examination 
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6. Reliable Digit Span (RDS) [31] – all results refer to a cut-off of ≤6. 
Study Sample (n) Age (SD) Education 
(SD) 
Impairment 
measure 
Impairment 
level 
*Specificity (%) Quality Rating score (CCAT) 
Loring et al., (2015) [47] AD (178) 75.7 (7.5) Not reported MMSE 23.3 (2) 87 31/40 (78%) 
aMCI (365) 74.9 (7.2) 27 (1.8) 96 
Controls (206) 76 (5) 29.1 (1) 97 
Kiewel et al., (2012) [48] Dementia 
(mild) 
74.6 (8.8) 14.5 (2.7) MMSE 23.4 (3.1) 89 30/40 (75%) 
Dementia 
(mod) 
76.5 (9.4) 14.2 (2.7) 16.8 (2.9) 76 
Dementia (sev) 71.2 (10.6) 13.5 (2.7) 7.7 (3.4) 17 
Dean et al., (2009) [18] Dementia 
(172) 
Not reported Not reported MMSE 19.2 (4.4) 70 30/40 (75%) 
*Specificity means that the test correctly identified optimal effort (i.e. the proportion of true negatives).    MMSE = Mini-Mental State Examination     aMCI = amnestic MCI 
 
 
7. Amsterdam Short-Term Memory Test (ASTM) [32] – results based on cut-off of 84/85. 
Study Sample (n) Age (SD) Education 
(SD) 
Impairment 
measure 
Impairment 
level 
*Specificity (%) Quality Rating score (CCAT) 
Merten et al. (2007) AD dementia 
(20) 
73.5 (4.8) 
 
11.7 (3.3) MMSE 22.2 (2.9) 
 
10 30/40 (75%) 
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Controls (14) 76.6 (6.7) 11.3 (3.7) 28.9 (1.0) 100 
*Specificity means that the test correctly identified optimal effort (i.e. the proportion of true negatives). 
MMSE = Mini-Mental State Examination 
  
 
 
8. Dot Counting Test (DCT) [33] – results based on ‘total ungrouped time<total grouped time’. 
Study Sample (n) Age (SD) Education 
(SD) 
Impairment 
measure 
Impairment 
level 
*Specificity (%) Quality Rating score (CCAT) 
Rudman et al., (2011) [36] Dementia 
(mild) (20) 
58.3 Not reported CAMCOG 88.60 (5.03) 90 28/40 (70%) 
Dementia 
(mod/sev) (22) 
62.45 (16.21) 68 
Dean et al., (2009) [18] Dementia (80) Not reported Not reported MMSE 18.8 (5) 50 30/40 (75%) 
*Specificity means that the test correctly identified optimal effort (i.e. the proportion of true negatives). 
CAMCOG = Cambridge Cognitive Examination   MMSE = Mini-Mental State Examination 
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1. Test of Memory Malingering (TOMM) [1]. 
Seven of the 20 papers included in this review investigated the use of the TOMM, one of 
the most widely used SVTs. The TOMM is a picture-recognition, forced-choice, purpose-
designed effort test created by Tombaugh (1996). It consists of two learning trials and an 
optional retention trial. Tombaugh provides a cut-off of <45 for Trial 2 and suggests that a 
score lower than this is indicative of poor effort.  
 
Across the seven studies, pass rates for the dementia groups (Trial 2 <45) ranged from a 
low of 24% [38] to a high of 95% [36]. Only two of the seven studies investigated the utility 
of the TOMM in MCI samples [38, 34]. Both studies found similar pass rates for these samples 
(91.7% and 90.3% respectively). 
Drawing comparisons between the results of these studies is compromised to an extent, 
because they use different criteria for diagnosing dementia (DSM-III, DSM-IV and the 
ADRDA-NINDS) and they also assess cognitive function using different tools (five report 
MMSE scores, one uses the RBANS and one the CAMCOG). This is important because one 
reason for the discrepancy in results across studies might be that the samples include 
individuals with significantly different levels of cognitive function. The difference in results 
reported by Tombaugh [1] and Teichner and Wagner [38] may be explained by dementia 
severity. Tombaugh states that 4/37 dementia participants (i.e. 10% of their dementia sample) 
who scored below 40 on the TOMM, had MMSE scores of 7, 15, 16 and 19. The paper does 
not, however, give any detail about the MMSE scores of the rest of the sample (presumably the 
remaining participants all of whom scored > 45 in this sample had MMSE scores of >19). In 
Teichner and Wagner’s [38] sample however, 9/21 (i.e. 42.9% of their dementia sample), had 
MMSE scores lower than 19. It may therefore be that Teichner and Wagner’s [38] sample was 
more cognitively impaired than that of Tombaugh’s [1]. Rudman and colleagues found a 
specificity of 95% for the TOMM, however this was in a sample of mildly impaired dementia 
participants. Specificity dropped to 36% in their moderate to severely impaired sample. 
 
There are also some flaws in the reporting of results across studies. Tombaugh [1] which 
received a score of 30/40 on the CCAT, states that ‘a cutting score of 45 on Trial 2 produced a 
high level of specificity. It correctly classified 95% of all non-demented patients (91% of all 
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patients) as non-malingering’ (p.265). When consulting information presented in a table 
however, 89.1% of Tombaugh’s [1] dementia sample passed the TOMM but only when a cut-
off score of <40 was used. This drops to 72.9% with the recommended cut-off of <45, meaning 
that approximately one in four of their dementia patients were incorrectly classified as putting 
forth sub-optimal effort. 
 
Additionally, with the exception of Bortnik et al. [35] sample sizes across studies were 
small. 
 
2. The Repeatable Battery for the Assessment of Neuropsychological Status 
(RBANS) [4]. 
The RBANS is a widely used neurocognitive battery commonly used in the assessment of 
dementia. Two RBANS embedded measures of effort have been developed: the Effort Index 
(EI) [24] and the Effort Scale (ES) [25]. Seven of the eight studies which investigated these 
embedded indices, examined the utility of the EI, four examined the utility of the ES and one 
paper compared both the EI and the ES against two novel RBANS embedded indices. 
 
a. RBANS Effort Index (EI) [24]. 
The EI combines performance on two subtests (Digit Span and List Recognition) to produce 
an ‘effort index’. A score of greater than 3 is suggestive of suboptimal effort. In the 
development of the EI, it was found that very poor performance on both these subtests was 
extremely rare in a mixed clinical sample of patients with neurological disorders.  
 
All 4 of the studies which use a reference standard in order to divide participants into 
optimal and sub-optimal effort groups, investigated the use of the EI. Sensitivity levels for the 
EI were 0.50, 0.89, 0.93 and 0.95. Unlike the TOMM studies, dementia severity does not appear 
to explain the differing sensitivity levels found for the EI. Bortnik et al. [35] who report a 
sensitivity level of only 0.50 in their ‘suspect effort’ dementia sample also report that this group 
had a mean MMSE score of 17.9. Compare this to Paulson et al. [26] who found a sensitivity 
level of 0.93 in a dementia sample with a mean MMSE score of 23.1. It should be noted 
however that the Bortnik study included a very small sample (n=9) and scored relatively poorly 
on the STARD (20/28) due to inadequate reporting. 
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Specificity levels were reported by all 6 papers and range from a low of 0.41[40] to a 
relative high of 0.69 [35]. Only controls and MCI samples produced acceptable levels of 
specificity on the EI. 
 
b.  RBANS Effort Scale (ES) [25]. 
The RBANS Effort Scale was devised by Novitski and colleagues and is based on the 
premise that when an individual has genuine memory impairment, their performance on free 
recall tasks (List Recall, Story Recall and Figure Recall subtests) will decline to close to zero 
before decline in List Recognition is seen. The authors of the ES propose a cut-off of <12 as 
being suggestive of sub-optimal effort (the ES calculation is: List Recognition – (List Recall + 
Story Recall + Figure Recall)) + Digit Span). 
 
The studies investigating the ES scored relatively poorly on the quality checklists due to 
inadequate and/or missing information making it difficult to examine the results across studies. 
In the original validation study, Novitski et al. [25] compared dementia and MCI participants 
with a poor effort group of mild head injury participants, they report an impressive area under 
the curve (AUC) of 0.908. The paper scored poorly however on the CCAT (21/40) due to 
inadequate information given regarding data collection, inclusion and exclusion criteria and 
participant demographic information.  
 
Burton et al. [39] compared the ES in AD and non-AD dementias. They found an 
impressively high specificity level of 0.96 in their AD sample, however this fell to 0.69 in their 
non-AD sample. The authors conclude that the ES may be an appropriate effort index to use 
when assessing effort level in people with a dementia of the Alzheimer’s type, however in 
clinician practice, effort tests are most likely to be given during the diagnostic process when a 
person’s diagnosis is as yet unknown. It does raise the issue that the ES is based on the premise 
that a person’s performance on tests of free recall will decline before their performance on tests 
of recognition. This profile of impairment is more likely to be seen in AD, which is 
characterised by a deficit in episodic memory, than in non-AD dementias. 
 
Paulson et al. [26] and Dunham et al. [40] investigated the ES in both good and suspect 
effort groups. They found sensitivity of 0.71 and 0.88 and specificity levels of 0.42 and 0.81 
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respectively. It is not clear why the studies found very different specificity levels and due to 
inadequate reporting by the studies it was impossible to investigate whether type of dementia 
had a bearing on the discrepancy in the results found (i.e. if the reason for the high failure rate 
in Paulson’s good effort group was due to the majority having a non-AD dementia). 
 
c. Performance Validity Index (PVI) [26] and Charleston Revised Index of Effort for 
RBANS (CRIER) [26] 
Paulson and colleagues evaluated the EI and ES against two novel RBANS embedded 
indices of effort, the PVI and the CRIER. The PVI cut-off for detecting invalid responding is 
<42 and is calculated as follows: 
 
RBANS PVI: List recall + story recall + figure recall + digit span + list recognition 
 
The CRIER cut-off for detecting invalid responding is <24 and is calculated as follows: 
 
RBANS CRIER: list recall + story recall + figure recall + digit span + list recognition – GDS 
 
The PVI was found to have sensitivity of 0.82, specificity of 0.77 and AUC of 0.90 whilst 
the CRIER had sensitivity of 0.84, specificity of 0.90 and AUC of 0.94. These are promising 
results and warrant further research. 
 
3. Effort tests using profile analysis: 
The WMT, MSVT and NV-MSVT, all devised by Green and colleagues, are SVTs which 
are a departure from the traditional pass/fail effort tests in that they use profile analysis to 
determine an individual’s level of effort. They are based on a hierarchical approach in line with 
the criteria devised by Slick et al. [7]. On these SVTSs, a participant’s score is firstly compared 
against a cut-off (a pass/fail approach) and then for those participants who fail, their profile of 
scores over several subtests is analysed. These tests are unique in that they allow the examiner 
to distinguish between failure due to poor effort and failure due to cognitive impairment. Green 
and colleagues state that on the WMT, MSVT and NV-MSVT, people with genuine cognitive 
impairment produce a specific profile of results, different from the pattern of results produced 
by those exerting sub-optimal effort. To differentiate between the two, the difference between 
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the mean scores on the easy and hard subtests is calculated. Individuals with a diagnosis of 
dementia invariably show easy-hard differences of at least 20 points on these subtests, whereas 
such significant differences are rarely present in people asked to feign impairment. This pattern 
of results is known as the ‘dementia profile’. These three effort tests are described and the 
literature evaluated in turn. 
 
a. Word Memory Test (WMT) [2, 49]. 
The WMT is a word-list learning task that involves learning a list of 20 word pairs which 
are presented twice, either on a computer screen or spoken aloud by the examiner (as in the 
original oral version of the test). It contains multiple subtests of which the first two are 
specifically designed to measure effort (Immediate and Delayed Recognition), the remaining 
subtests are conventional memory subtests. As stated above, the profile of scores on the WMT 
subtests (particularly the difference between the effort subtests and the conventional memory 
subtests) can indicate whether individuals fail the test due to insufficient effort or to the severity 
of their cognitive impairment.  
Merten et al. [37] found that whilst all their controls passed the WMT effort subtests, almost 
all of the AD participants failed it (90% failed both the Immediate and Delayed Recognition 
trials). It is important to note however, that the authors were not able to analyse the profile of 
scores on the two effort subtests against those of the conventional memory tests because 
normative data for a Dutch population were not available at the time of the study. This is a 
significant limitation of the Merten et al. [37] study since the researchers were only able to look 
at whether participants passed or failed the effort subtests and were not able to look at the 
profile of their scores to investigate whether they indicated a ‘dementia profile’. 
A study in 2011 by Green et al. [42] found that 41/65 (63%) of their dementia sample and 
13/60 (21.6%) of their MCI sample failed the easy subtests of the WMT. Using profile analysis 
however they found that every participant with dementia exhibited a ‘dementia profile’ 
meaning there were no false positives. Regarding the MCI sample, only 2 of the 11 participants 
who failed the easy subtests of the WMT, indicated a profile suggestive of poor effort, which 
represents a false-positive rate of 3.3%. The study however scored 28/40 on the CCAT due to 
inadequate reporting such as missing demographic data. It should perhaps also be noted that 
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the participants were not screened for potential financial incentives, meaning that it cannot be 
concluded that the 2 participants who generated a poor effort profile were real false-positives. 
 
b. Medical Symptom Validity Test (MSVT) [27]. 
The MSVT is a shorter, modified and easier version of the WMT.  
 
Four of the papers in this review examined the utility of the MSVT in people with dementia, 
MCI, cognitively intact controls and volunteers asked to simulate dementia. Two of the papers 
were able to report sensitivity levels of 60% (simulators) and 100% (suspect effort MCI 
sample). Specificity levels for the MSVT across the 4 studies ranged from 80 -100% with the 
exception of Rudman et al. [36] who calculated effort based on whether participants had passed 
or failed the effort subtests. They did not use profile analysis. Although these results are 
promising, they should be treated as preliminary as the studies involved very small sample 
sizes. 
 
c. Non-Verbal Medical Symptom Validity Test (NV-MSVT) [28]. 
The NV-MSVT is the non-verbal equivalent of the MSVT. Three studies were found to 
investigate the diagnostic accuracy of this SVT in dementia and healthy controls. 
 
As noted with the MSVT, Rudman et al. [36] found low specificity of the NV-MSVT (33% 
in their overall dementia sample), however they did not use profile analysis therefore their 
results are not complete or accurate. Henry et al. [45] found specificity of 100% in their controls 
and dementia sample and 97.7% in their non-dementia (neurological) sample whilst Singhal et 
al. [43] found 100% specificity for their institutionalised dementia patients. Interestingly, 
Singhal’s entire dementia sample failed the effort subtests of the NV-MSVT however they all 
showed a ‘dementia profile’ therefore they were not misclassified as malingering. They were 
also a particularly impaired sample (average MMSE of 15.5).  
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4. Rey 15 Item Test (RFIT) [3, 29]. 
Alongside the TOMM, the RFIT is one of the most widely used effort tests in clinical 
practice [50]. The task consists of studying a card for 10 seconds which has five rows of three 
characters. The test consists of a free-recall and an optional combination equation. A score 
lower than 9 on the free-recall trial and a score lower than 20 on the combination equation are 
said to be indicative of suboptimal effort [29]. 
 
Bortnik et al. [35] reported a high sensitivity to sub-optimal effort in their ‘suspect effort’ 
group (100%) but a very low specificity (28%) in their good effort group. Rudman et al. [36] 
found a similar specificity level (27%) for their moderate/severe dementia group. The studies 
use different tools to assess cognitive impairment (MMSE and CAMCOG) however research 
suggests these screens are highly correlated [50] therefore it was possible to note that both 
Rudman and Bortnik’s dementia samples were equally impaired (mean CAMCOG 62.45, mean 
MMSE 20.8). Rudman found far better specificity in their mildly impaired sample (85% 
specificity, mean MMSE 20.8). Both studies performed similarly on the quality rating 
checklists (70%). 
 
5. The Coin in the Hand (CIH) [30]. 
The Coin in the Hand Test was developed by Kapur (1994) [30] to be a ‘simple, brief test 
designed to detect the presence of malingering in patients who are suspected of simulating poor 
memory performance’ (p.385). It is a stand-alone, forced-choice test where the clinician holds 
a coin in their right or left hand in front of the examinee who then closes their eyes and counts 
backwards from 10 before opening their eyes to report which hand the coin is in. A score of 7 
or less out of 10 trials is used as the cut-off for this test.  
 
Two of the papers included in this review examined the utility of the CIH. Schroeder et al. 
[46] used a sample of 45 inpatients with a diagnosis of dementia. The Schroeder study 
performed fairly well on the CCAT (31/40). In order to ensure that their sample would put forth 
adequate effort on the CIH, Schroeder excluded participants involved in litigation or who were 
collecting disability payments and they also excluded any participant failing the RBANS Effort 
Scale. Using a cut-off score of ≤7, resulted in a specificity of 98% in the Schroeder sample. 
Using the same cut-off, Rudman found specificity of 100% in their mild dementia sample 
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compared to 77% in the moderate/severe sample. Specificity therefore is high with a CIH cut-
off of ≤7 as long as the examinee is not too cognitively impaired. 
 
6. Reliable Digit Span (RDS) [31]. 
Greiffenstein, Baker, and Gola [52] originally derived the RDS from the Digit Span 
subtest of the Wechsler Adult Intelligence Scale–Revised (Wechsler, 1981) by ‘summing the 
longest string of digits repeated without error over two trials under both forward and backward 
conditions’ (pp. 219-220). 
 
RDS specificity was found to be greatly impacted by severity of cognitive impairment. It had 
high specificity for Loring’s dementia (87%), MCI (96%) and control samples (97%) whilst 
Kiewel found high specificity for their mild dementia sample (89%). All of these samples had 
MMSE scores of 23 or more. In contrast, with Kiewel’s more impaired groups, the RDS 
yielded an unacceptable level of false positives similar to those in the equally impaired Dean 
study. 
 
7. Amsterdam Short Memory Test (AMST) [32]. 
The AMST is a forced-choice test where five examples from a category (e.g. animals, 
colours etc.) are read aloud by the examinee. A relatively simple mathematical problem is then 
presented to the examinee after which time another five words from the same category are 
presented. The examinee’s task is to recognise which three words are identical to those in the 
first list. The test maximum score is 90 and the cut-off is 84/85. Merten et al. [37] found that 
all of their controls passed the ASTM however only 10% of their Alzheimer’s dementia 
participants passed the test (i.e. specificity, 10%). Given that 70% of the same AD sample 
passed the TOMM, it would appear that the ASTM is unlikely to be an appropriate choice of 
SVT for individuals with cognitive impairment due to a possible dementia because the false-
positive rate is likely to be high. 
 
8. Dot Counting Test (DCT) [33]. 
The DCT was originally devised by Rey in 1941 and is a task where the examinee is 
presented with twelve cards containing different numbers of dots. The first six cards contain 
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dots arranged in a random order and the following six cards contain grouped dots. Examinees 
are asked to count the dots as quickly as possible. Suspect effort is considered if the time taken 
to count the grouped dots is equal to or more than the time required to count the ungrouped 
dots [53]. 
 
Similar to the results found for the RFIT, Rudman and Dean found low specificity (50% 
and 68% respectively) in their more impaired samples whereas Rudman found relatively high 
specificity in their mild dementia sample (90%).  
 
Discussion 
This review included 20 papers examining the diagnostic accuracy of 12 embedded and 
stand-alone tests of effort in dementia and MCI samples. In particular this review sought to 
establish which SVTs were most sensitive to sub-optimal effort whilst being insensitive to the 
cognitive impairment seen in individuals who meet criteria for these diagnoses. The effort tests 
which were found to be most sensitive to sub-optimal effort whilst being least sensitive to 
dementia-related cognitive impairment were the three SVTs devised by Green et al [2, 27, 28]. 
The WMT, MSVT and NV-MSVT go beyond the pass/fail approach of traditional effort tests 
and instead use profile analysis to determine if the pattern of results which an examinee 
produces are indicative of poor effort or if they show a ‘dementia profile’. The vast majority 
of the studies which investigated these tests found 100% specificity. The only studies which 
found low levels of specificity for these SVTs were those which calculated Criterion A only 
and did not use profile analysis to determine effort level (i.e. determined effort level on whether 
the participants scored below cut-off on the effort tests but did not determine whether a 
dementia profile was present). The WMT, MSVT and NV-MSVT therefore appear to be the 
most appropriate effort tests for use in cognitive assessment when a dementia is queried. These 
results should be taken as provisional however since, although the evidence is promising there 
is not a wealth of literature to draw from. Future research may also seek to further evaluate the 
use of the two new RBANS embedded indices (PVI and CRIER) created by Paulson and 
colleagues as these showed good potential and the RBANS is a commonly used tool in older 
adult memory clinics in the UK. 
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Methodological limitations of effort testing literature 
Compared to other areas of research in clinical neuropsychology, effort testing research 
faces significant methodological challenges since no ‘gold-standard’ exists with which to 
reliably determine performance validity. Five of the 19 papers included in this review 
attempted to independently assess effort by use of a reference standard (three used the TOMM, 
one used the MSVT and one used the RBANS Effort Scale). The remaining 14 papers either 
excluded participants who may have had an incentive to feign impairment or they assumed 
good effort by virtue of the participants having a diagnosis of dementia. This makes it difficult 
to know what the true false-positive rate actually is. 
 
Diagnostic tests should be evaluated in samples that are representative of those with 
whom the test will be used in practice. The majority of the studies included in this review use 
a methodology whereby participants with an established dementia are compared to healthy 
controls. This is likely to lead to bias since the participants included have a more advanced 
stage of the disease (in this case dementia) than studies using a clinical sample of consecutive 
referrals to memory clinics. Indeed there appears to be a positive correlation between SVT 
specificity and severity of cognitive impairment, such that as scores on cognitive tests decrease, 
so too does the specificity level of an SVT. 
  
Also, very few of the studies included samples with a diagnosis of MCI, a population 
of importance when evaluating the diagnostic accuracy of effort tests in older adults presenting 
with memory difficulties. Additionally, very few of the studies included in this review were 
able to assess sensitivity levels because they only included participants who were deemed to 
exert optimal effort from the outset, either due to not being involved in litigation/claiming 
disability benefits or simply by virtue of having a diagnosis of dementia.  
 
Finally, the studies included in this review largely approach the subject of effort in its 
‘malingering’ definition whereby examinees are deemed to be feigning impairment. As 
discussed previously, indications of poor or atypical motivation are not always the result of 
deliberate malingering, rather there are many reasons for an individual to put forth less than 
optimal effort such as low mood, stress, conversion disorder, medication side effects and 
fatigue amongst others. The majority of the studies in this review did not assess for these factors 
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Methodological limitations of the current review 
This systematic review faced some methodological limitations. Firstly, it was out with 
the scope of the review to include every study which has investigated the diagnostic utility of 
SVTs in dementia samples. The current study focused on papers which included dementia/MCI 
samples as their primary interest. There are, however, other studies which include a dementia 
sample alongside other clinical samples. Additionally, as previously mentioned, it was also out 
with the scope of the current review to examine every SVT investigated by the papers included 
therefore only the SVTs which are known to be most used in clinical practice were reviewed. 
 
Finally, some of the studies examined the performance of the SVTs across different 
cut-offs. It was not possible to review each of these cut-offs therefore those most used in 
clinical practice were evaluated. 
 
Conclusions 
Future research on the diagnostic accuracy of SVTs in older adults should aim to focus 
on the recruitment of consecutive referrals to memory clinics and should employ a multi-
method approach such as that proposed by Slick et al. [7]. As part of the cognitive test battery, 
the participants should receive a reference standard (such as the MSVT or NV-MSVT) and the 
SVT of interest (the index test). The index test should only be calculated once the final 
diagnosis is known. This method would allow for both sensitivity and specificity of the SVT 
in question to be investigated since both good effort and suspect effort participants would be 
included. Future research should also seek to review the diagnostic utility of SVTs across 
various cut-offs in MCI/dementia samples. 
 
Following evaluation of the studies in this review, tests which take a hierarchical 
approach to effort testing such as the WMT, MSVT and the NV-MSVT may be the best SVTs 
to use in clinical practice given that these tests have been found to be particularly robust in 
dementia samples (i.e. they have very low false-positive rates). 
 
Finally it must be stressed that determining an individual’s level of effort should not be 
judged on the basis of scores on an effort test alone. It should also be noted that the vast majority 
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of older people referred for memory assessment will have no incentive to purposefully feign 
impairment. 
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Chapter 2: Major Research Project 
 
An Investigation of the Utility of the Mini Addenbrooke’s Cognitive Examination (M-
ACE) for the Early Detection of Dementia and Mild Cognitive Impairment in People 
Aged 75 and Over 
(Prepared in accordance with Dementia and Geriatric Cognitive Disorders guidelines) 
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Plain English Summary 
Title: An Investigation of the Utility of the Mini Addenbrooke’s Cognitive Examination (M-
ACE) for the Early Detection of Dementia and Mild Cognitive Impairment in People Aged 75 
and Over. 
Background: Cognitive screening tools are crucial for the accurate detection and differential 
diagnosis of dementias.  The Mini Mental State Examination (MMSE) [1] is the most popular 
short screen used in clinical UK settings and is recommended by both the Scottish 
Intercollegiate Guidelines Network (SIGN) and the National Institute for Clinical Excellence 
(NICE). The MMSE has however been found to have several drawbacks such that it is less 
sensitive to mild cognitive impairments (MCI) and is prone to ceiling and floor effects [2]. An 
alternative resource is the Mini-Addenbrooke’s Cognitive Examination (M-ACE) [3] which is 
a shortened version of the widely used Addenbrooke’s Cognitive Examination III (ACE-III). 
The current study investigated the utility of the M-ACE at detecting dementia in people aged 
75. The study focused on over 75s as this is the fastest growing section of our population, 
projected to increase by 75% by 2031 [4]. 
Aims: This study aimed to investigate if the M-ACE can be used with people aged 75 and over 
to distinguish between those who do and do not have a diagnosis of dementia. It also aimed to 
investigate whether the cut-off scores recommended by Hsieh et al. (2014) [3] in the original 
validation study for the M-ACE are optimal for an older population. 
Participants: Participants were people aged 75 and over who were referred to Community 
Mental Health Teams (CMHTs) in Glasgow. There was also a group of participants who did 
not have memory problems, all of whom were the spouses/carers of patients receiving care 
from a CMHT. 
Recruitment: Participants were given information about the study on their first contact with 
the CMHT. If they gave consent to take part they were contacted again by telephone to arrange 
a home visit. 
 
Consent: Informed consent was given by participants via a signature on a consent form. 
 47 
 
 
Study Design: There were three groups of participants: a dementia group, a group with mild 
cognitive impairment (MCI) and a control group (who do not have memory problems). All 
participants had their cognitive function assessed using the M-ACE. 
Data Collection: Participants referred to the CMHT for memory problems were introduced to 
the project by a member of staff involved in their care. They were provided with an information 
sheet and if they gave verbal consent to be contacted with regards the study, the primary 
researcher arranged a home visit to carry out the M-ACE. 
Ethical Issues: Participants were fully briefed on the implications of having their cognition 
assessed.  
Main Findings and Conclusions: The optimal cut-off for detecting dementia was ≤21/30, 
lower than the original published cut-off of ≤25/30 by Hsieh et al. [3]. The M-ACE has 
excellent diagnostic accuracy for the detection of dementia in a UK clinical sample. 
References: 
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3. Hsieh S, McGrory S, Leslie F, Dawson K, Ahmed S, Butler CR, et al. The Mini-
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Abstract 
Background/Aims: The Mini Addenbrooke’s Cognitive Examination (M-ACE) is the 
abbreviated version of the widely-used Addenbrooke’s Cognitive Examination (ACE-III), a 
cognitive screening tool that is used internationally in the assessment of mild cognitive 
impairment (MCI) and dementia.  The objectives of this study were to investigate the diagnostic 
accuracy of the M-ACE with individuals aged 75 and over to distinguish between those who 
do and do not have a dementia or MCI, and also to establish whether the cut-off scores 
recommended by Hsieh et al. (2014) [9] in the original validation study for the M-ACE are 
optimal for this age group. Methods: The M-ACE was administered to 58 participants (24 with 
a diagnosis of dementia, 17 with a diagnosis of MCI and 17 healthy controls). The extent to 
which scores distinguished between groups (dementia, MCI or no diagnosis) was explored 
using receiver operating characteristic curve analysis. Results: The optimal cut-off for 
detecting dementia was ≤ 21/30 (score ≤ 21/30 indicating dementia with a sensitivity of 0.95, 
a specificity of 1 and a positive predictive value of 1) compared to the original higher published 
cut-off of ≤ 25/30 (sensitivity of 0.95, specificity of 0.70 and a positive predictive value of 0.82 
in this sample). Conclusions: The M-ACE has excellent diagnostic accuracy for the detection 
of dementia in a UK clinical sample. It may be necessary to consider lower cut-offs than those 
given in the original validation study. 
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Introduction 
Dementia describes a set of symptoms that may include memory loss and difficulties 
with thinking, problem-solving or language [1]. As of 2015, there were an estimated 46.8 
million people living with dementia throughout the world, with this number expected to double 
every 20 years, reaching an estimated 74.7 million by 2030 [2]. Although diagnosis rates have 
improved in recent years, it is estimated that there are still approximately a third of those with 
dementia who do not have a diagnosis. It has been recognised that although dementia has a 
profound impact on the individual and their family, a timely and accurate diagnosis can lead to 
better support, can enable people to maintain a good quality of life at home for as long as 
possible and can also empower them to make their own choices about their future care [3]. 
 
The use of cognitive screening tools in dementia assessment 
In order to provide appropriate support to individuals with dementia, it is first necessary 
to be able to make an accurate diagnosis. Cognitive screening tools are an important part of 
dementia assessment. These tools indicate whether an individual’s cognitive difficulties fall 
within an expected range for their age or whether there is a need for further investigation such 
as neuroimaging or neuropsychological assessment. Cognitive screening tools can also inform 
differential diagnosis between different types of dementia or other conditions which can cause 
cognitive impairment.  
 
One of the most popular cognitive screening tools is the Mini Mental State Examination 
(MMSE) [4] which has been used worldwide to detect dementia for the past three decades. The 
MMSE is a 30-point questionnaire that takes 5-10 minutes to administer. It is often used to 
track changes in a person’s cognitive function which helps to either aid a diagnosis of dementia, 
or if already diagnosed, to determine what stage the person is at. However, despite its popularity 
the MMSE has been found to have several weaknesses, including poor sensitivity to mild 
cognitive impairment and it is also prone to ceiling and floor effects [5]. The test also relies 
heavily on verbal items which is problematic when using the test with individuals with poor 
language skills and/or low education [6]. A further disadvantage to using the MMSE is a 
 50 
 
 
financial one: the test has been placed under copyright since 2001, incurring a cost of 80p every 
time it is used [7]. This clearly has financial implications for healthcare providers who face 
either continuing to pay for continued access to the MMSE or finding an alternative resource. 
 
Due to an increasing awareness of the insufficient assessment provided by the MMSE, 
other cognitive tests have been developed which aim to examine cognitive domains not 
assessed by the MMSE whilst remaining relatively brief. One of the most popular of these 
extended tests is the Addenbrooke’s Cognitive Examination (ACE) which was introduced in 
2000 as a brief cognitive screening tool which incorporated the MMSE but also explored 
important areas not covered by it, such as visuospatial skills, frontal-executive function and 
more complex language assessment. The ACE is a 100-point test battery which takes 
approximately 15-20 minutes to administer. The validation study of the first version of the 
ACE showed that it was superior to the MMSE in both detecting dementia and differentiating 
between Alzheimer’s disease and fronto-temporal dementia [8]. The ACE, which is now in its 
third version (the ACE-III, Neuroscience Research Australia, 2012), is recommended by both 
National Institute of Clinical Excellence (NICE) and the Scottish Intercollegiate Guidelines 
Network (SIGN) as an extended screening to be used when clinicians require a more detailed 
picture of a patient’s cognitive function. Despite the ACE-III being a robust screening tool, the 
time taken to complete it means that it is not always a viable option in busy clinics. Whilst 
clinicians should aim to complete as comprehensive an initial cognitive screen as possible, in 
practice this is not always viable, meaning that clinicians need to have the option of a very brief 
measure for such occasions. 
 
The M-ACE as a cognitive screening tool and its adjusted cut-offs 
The focus of the current study concerns one such new brief screening tool: the Mini 
Addenbrooke’s Cognitive Examination (M-ACE) [9] which is a shortened version of the ACE. 
The M-ACE takes under 5 minutes to administer and contains 5 items assessing orientation, 
memory, category fluency and clock drawing. It is scored out of 30 with two cut-offs 
recommended: (1) 25/30 and (2) 21/30.  The higher cut-off of 25/30 has both high sensitivity 
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and specificity and is at least 5 times more likely to have come from a patient with dementia 
than without. The lower cut-off of 21/30, by contrast, is almost certainly diagnostic of a 
dementia syndrome regardless of the prevalence rate. This is important because a test’s 
diagnostic accuracy will vary with disease prevalence [10]. The M-ACE validation study 
showed that the M-ACE is more sensitive than the MMSE and is less likely to have ceiling 
effects. There is a need to further explore the M-ACE and its potential as a brief screening tool 
which is the purpose of the current study. 
 
The current study 
The initial validation study for the M-ACE was conducted in Australia therefore there 
is a requirement for the utility of the M-ACE to be investigated in a UK clinical setting. The 
focus of the current study was on individuals aged 75 and over who are referred to a 
Community Mental Health Team (CMHT) for memory problems. A control group of healthy 
individuals with no history of memory problems were also aged 75+. There are several reasons 
for focusing on this age group. One reason is that age is a key risk factor for developing a 
dementia. The prevalence of dementia in people aged 70-74 is 3% which rises to 6% for 75-79 
olds and 11.1% for 80-84 year olds [11]. 
 
Further, with increased improvements in healthcare there is going to be a significant 
increase in the proportion of people aged 75+ in the population. By 2031 the number of people 
aged 75+ is projected to increase by 75% [12]. In Scotland alone this figure is projected to 
increase to 94,000 by 2017 and 108,000 by 2022; with incidence of 9,400 and 10,800 
respectively. This represents a 12% increase by 2017 and a 29% increase by 2022. [13]. This 
creates a challenge for our health and social care services that will increasingly be called on to 
meet the needs of this population. 
 
A third reason for this focus comes from a limitation of the original M-ACE validation 
study by Hsieh et al. [9]. This study was limited to comparing patients with controls in the age 
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range 61-74 therefore the validity of the tool has not been demonstrated in the age range of 
people most likely to present to memory clinics. As people get older, they may be more suited 
to a shorter cognitive test as they may have more visual, auditory or concentration difficulties 
than younger patients. 
 
There is also a need to investigate the optimal cut-offs for the M-ACE for 
discriminating between those who have a diagnosis of dementia in people aged 75+. A recent 
study found that the optimal cut-offs for the ACE-III for people over the age of 75 in a UK 
clinical sample were lower than those recommended in the ACE-III validation study [14]. This 
is also the case for other brief cognitive screens. Oren et al. [15] found that 42% of their 
cognitively-intact sample who were aged 80 and over scored below the recommended cut-offs 
proposed by the authors of the Montreal Cognitive Examination (MoCA). 
 
Objectives 
The primary objective of this study was to investigate the diagnostic accuracy of the 
M-ACE in people aged 75 and over to distinguish between those who do and do not have a 
diagnosis of dementia and those who have a diagnosis of MCI. The secondary objective was 
to investigate whether the cut-off scores recommended by Hsieh et al. [9] in the original 
validation study for the M-ACE are optimal for this older age group. 
 
Primary hypothesis 
It was hypothesized that there would be a significant difference in the M-ACE scores 
for the three groups of participants i.e. those who have a diagnosis of dementia, MCI or no 
diagnosis. Furthermore it was predicted that the score on the M-ACE would accurately 
discriminate between those who have a diagnosis of dementia, MCI and those who have no 
diagnosis in those aged 75 and over. It was predicted that the minimum level of 
sensitivity/specificity would be at least as good as those found for the original M-ACE study 
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(i.e. ≤ 25/30, sensitivity of 0.85, specificity of 0.87 and ≤21/30, sensitivity of 0.61, specificity 
of 1). 
 
Secondary hypothesis 
It was also hypothesized that the optimal cut-off for discriminating between those who 
have a diagnosis of dementia would be lower in this sample of participants aged 75 and over 
than those suggested in the Hsieh et al. [9] original validation study. This is because previous 
research investigating the diagnostic accuracy of cognitive screens in older populations found 
that the optimal cut-offs were lower than those reported in the original validation studies [14, 
15]. It is also expected that cognitive ability will naturally decline with age. 
 
Methods 
Participants - Clinical samples (MCI and dementia) 
Participants with a diagnosis of MCI and dementia were recruited from five Older Adult 
Community Mental Health Teams (CMHTs) across NHS Greater Glasgow and Clyde.   
Inclusion criteria. All participants: 
1. Were aged 75 and over. 
2. Had previously completed the ACE-III as part of routine clinical care. 
3. Were able to give informed consent. 
4. Spoke English as their first language. 
 
Exclusion criteria 
There was minimal exclusion criteria for the MCI and dementia groups since the study 
aimed to use a sample of all patients referred to CMHTs for memory problems over the time 
period of the study. However patients in the dementia and MCI groups were not recruited to 
the study if they: 
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1. Were experiencing cognitive impairment due to another neurological condition (e.g. 
due to head injury, alcohol-related damage, epilepsy). 
2. Had significant hearing or vision problems which would prevent their completion of 
the M-ACE. 
3. Had a learning disability (meaning that no participant had a significantly reduced ability 
to understand new or complex information or to learn new skills; a reduced ability to 
cope independently or an impairment that started before adulthood, with a lasting effect 
on development.). 
 
Participants - Control group 
Inclusion criteria 
All participants were aged 75 and over and spoke English as their first language. 
 
Exclusion criteria 
Control participants were not recruited to the study if they: 
1. Had a significant hearing or vision problems which would prevent their completion of 
the M-ACE. 
2. Had a neurological condition. 
3. Had a learning disability. 
4. Had prior history of memory problems.  
 
Justification of sample size 
The sample size required was based on a power calculation for a one-way ANOVA as this 
was the planned method for statistical analysis. The original validation study of the M-ACE 
(Hsieh et al., [9]) does not report an effect size, therefore the validation study for the ACE-R 
informs the likely effect size for the current study [16]. In Mioshi et al., [16] Cohen’s d for the 
difference between controls and those with Alzheimer’s dementia was 1.84, which is a large 
effect size. GPower (v 3.1.9.2) [17] was used to calculate sample size. In order to detect a large 
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effect size (Cohen's f= .40) with α = 0.05, on a one-way ANOVA, 66 participants would be 
required across the three groups (22 participants in each group).  
 
Measures 
The Mini Addenbrooke’s Cognitive Examination (M-ACE) was the primary outcome 
measure and is available free of charge at: https://www.neura.edu.au/frontier/research/test-
downloads/. 
 
Recruitment Procedure 
All participants in the dementia and MCI groups were patients referred to the CMHT for 
assessment of cognitive difficulties. All of the participants in the control group were the 
spouses/carers of patients receiving input from the CMHTs for MCI/dementia.  
 
Research Procedure 
Dementia and MCI group participants 
Patients with a diagnosis of dementia or MCI who met the inclusion criteria were 
approached to take part by members of the clinical team. Staff members introduced the current 
study to patients who had a diagnosis of either dementia or MCI during routine home or clinic 
appointments by providing them with an information sheet and a letter of invitation (See 
Appendices 2.5 and 2.6). If the patient expressed an interest in taking part, the member of staff 
passed their details (name, address and telephone number) to the primary researcher in order 
for them to arrange a home visit. The primary researcher then carried out a home visit to further 
explain the study, answer any questions the participant may have had and gain written consent 
(see Appendix 2.7). The primary researcher then carried out the M-ACE. 
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During the course of the study, it became clear that there were fewer participants with MCI 
being recruited to the study than dementia or control participants. This is because, at present, 
clients who are given a diagnosis of MCI are usually discharged back to the care of their GP 
within a short timeframe. A new procedure was developed which involved members of the 
clinical team posting out information sheets (see Appendices 2.11 and 2.12) to clients with a 
diagnosis of MCI who had received input from the CMHT within the last two months. After a 
period of one week, the clinician who had provided their care telephoned the participant to 
enquire if they wished to take part in the current study. If so, the primary researcher visited the 
client at home to further explain the study, gain written consent and complete the M-ACE. 
 
Control group participants 
If there was a carer or relative present on the clinical team member’s home visit who was 
aged 75+ and did not meet exclusion criteria (see above), they were approached to take part in 
the study. If the carer/relative wished to take part, they were provided with an information sheet 
(Appendices 2.8 and 2.9) and the member of staff passed on their details to the primary 
researcher who contacted the carer/relative by telephone in order to arrange a home visit. The 
primary researcher then carried out a home visit to further explain the study, gain written 
consent (see Appendix 2.10) and carry out the M-ACE. Some control participants were also 
recruited from carers’ groups held at the various CMHTs involved in the study. 
 
Ethical approval 
Ethical approval was gained from the West of Scotland Research Ethics Committee 3 
(15/WS/0279) and practice was informed by the British Psychological Society Code of Ethics 
and Conduct (2009) [18]. 
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Statistical analysis 
Statistical analyses were performed using either SPSS (Version 24) [19] or Medcalc 
(Version 16.4.3) [20]. Preliminary analyses included testing the data for normality (Shapiro-
Wilks). Some of the variables were normally distributed and some were not, therefore both 
parametric and non-parametric statistical tests were used. A one-way ANOVA was used to 
examine if there were significant differences between the three groups with regards M-ACE 
score. The non-normally distributed variables of age, years of education and M-ACE subscales 
were examined using the Kruskal Wallis. The relationship between the participants’ years of 
education and M-ACE scores and their age and M-ACE scores was calculated using 
Spearman’s rank-order correlation coefficient. Analysis of the M-ACE diagnostic accuracy 
was explored using receiver operating characteristic (ROC) curves. This provided sensitivity 
and specificity values for a range of M-ACE scores and the area under the curve (AUC) which 
is an overall measure of discriminative power. Additional statistics were calculated, namely, 
positive and negative likelihood ratios (LR+, LR-), Youden index and positive and negative 
predictive values (PPV, NPV). The impact of disease prevalence on the performance of the M-
ACE for various cut-offs was also explored by calculating PPV and NPV for various 
prevalence levels.  
It had been intended to examine the relationship between a participant’s score on the M-
ACE and their score on the ACE-III. Unfortunately most of the participants in this study had 
completed the ACE-III more than 6 months before administration of the M-ACE meaning that 
it was inappropriate to compare these scores. 
 
Results 
Preliminary Analyses 
In total, 58 participants were recruited to the study: 24 participants in the dementia group, 
17 in the MCI group and 17 in the control group. 
Initial analysis was undertaken to determine whether the data set was normally distributed. 
The Shapiro-Wilks test was undertaken for M-ACE scores, age, years of education and the 5 
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subscales of the M-ACE (Attention, Immediate Memory, Fluency, Visuospatial and Delayed 
Memory). The null hypothesis of the Shapiro-Wilks test is that the data are normally distributed.  
The null hypothesis was retained for the M-ACE scores suggesting that the data for this 
variable were normally distributed. This means that the M-ACE scores for the dementia group 
(W = 0.975, p = .796, n.s), the MCI group (W = 0.952, p = .481, n.s) or the control group (W 
= 0.963, p = .688, n.s) did not deviate significantly from normal.  
The null hypothesis was rejected however for age and years of education. Age was normally 
distributed in both the dementia (W = 0.954, p = .323, n.s) and MCI groups (W = 0.919, p 
= .142, n.s) however it deviated significantly from normal for the control group (W = 0.830, 
p=<.005). Years of education for the dementia group (W = 0.831, p = <.001), MCI (W = 0.616, 
p =<.001) and control group (W = 0.828, p=<.005) all deviated significantly from normal. 
None of the 5 M-ACE subscales were normally distributed (Attention, W =0.774, p =<.001, 
Immediate Memory, W =0.845, p =<.001, Fluency, W=0.924, p=.001, Visuospatial, W=0.797, 
p =<.001, Delayed Memory, W=0.899, p =<.001). 
Therefore, subsequent analysis for M-ACE scores used parametric tests whilst for the non-
normally distributed variables (age, years of education and M-ACE subscales) non-parametric 
tests were used. 
Demographic details for the three groups of participants were analysed and are presented 
in Table 1 below. 
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Table 1. Demographic details of participants by group. 
 
Dementia 
(n=24) 
MCI 
(n=17) 
Controls 
(n=17) 
Gender 
Male (%) 
Female (%) 
 
9 (37.5) 
15 (62.5) 
 
4 (23.5) 
13 (76.5) 
 
6 (35.3) 
11 (64.7) 
Age, years 80 (7)  79 (7) 78 (6) 
Education, years  11 (2) 10 (2) 11 (4) 
M-ACE score  
(max score 30) 
(mean and SD) 
14.8 (4.9) 20.9 (3.8) 26.5 (2.2) 
*Figures are median values with interquartile range in parentheses unless otherwise stated. 
 
 
In the overall sample, there were 19 (32%) males and 39 (68%) females with ages 
ranging from 75 to 89. Of the dementia group, 13 (54.2%) had Alzheimer’s dementia, 8 (33.3%) 
had vascular dementia, 1 (4.2%) had Lewy body dementia and 2 (8.3%) had a mixed type 
dementia. Fourteen participants in the dementia group (58.3%) were taking a cognitive 
enhancer at the time of testing. 
 
Primary hypothesis 
It was hypothesized that there would be a significant difference in the M-ACE scores 
for the three groups of participants, i.e. those who have a diagnosis of dementia, MCI or no 
diagnosis.  
A significant difference was found between the groups for M-ACE score (F (2, 55) = 
43.5, p = <.001) and a Tukey post-hoc test revealed that the all the groups differed significantly 
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from each other with regards M-ACE score. Unsurprisingly, the control group performed 
significantly better on the M-ACE (26.5 ± 2.2) than the MCI group who in turn performed 
significantly better (21 ± 3.8) than the dementia group (14.8 ± 4.9). 
A Kruskal-Wallis test showed that there was no significant difference between the 
groups concerning age (X2 (2) =3.242, p = .198, n.s) but that there was a significant difference 
for years of education (X2 (2) =7.206, p=.027). The effect size for years of education was 0.14. 
Further analysis using Kruskal-Wallis found a significant difference between the MCI and 
dementia (X2 (1) = 5.299, p = .021) and the MCI and controls X2 (1) = 5.473, p = .019) 
regarding years of education. The MCI group had significantly less years of education (9.82 ± 
2.19) than either the dementia (11.5 ± 2) or control groups (12 ± 2.38). The dementia and 
control groups did not differ significantly (X2 (1) = .317, p = .573) on this variable.  
A Spearman’s correlation was run to determine if there existed a significant relationship 
between M-ACE score and years of education and M-ACE score and age for each of the groups.  
There was no significant relationship found between M-ACE score and years of education for 
any of the groups (dementia, rs (24) = .125, p = n.s, MCI, rs (17) = -.320, p = n.s, control, rs 
(17) = .066, p = n.s). There was no significant relationship between M-ACE score and age for 
any of the groups (dementia, rs (24) = -.064, p = n.s, MCI, rs (17) = -.058, p = n.s, control, rs 
(17) = -.243, p = n.s).  
A Kruskal-Wallis was also carried out to determine if there was a statistically 
significant difference between the groups with regards the different subscales which make up 
the M-ACE (Attention, Immediate Memory, Language, Visuospatial and Delayed Memory). It 
was revealed that the groups differed significantly regarding performance on all domains 
(Attention, X2 (2) = 22.874, p = .000, Immediate Memory, X2 (2) = 23.185, p =.000, Fluency, 
X2 (2) = 31.475, p =.000, Delayed Memory, X2 (2) = 26.221, p =.000) with the exception of 
visuospatial (Visuospatial, X2 (2) = 4.580, p = .101, n.s). 
The results of further analysis for the subscales can be found in Table 2.  
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Table 2. Significance levels for subscales by group. 
Attention Asymp. Sig 
Dementia 
MCI .020 
Control .000 
MCI Control .006 
Immediate Memory 
Dementia 
MCI .003 
Control .000 
MCI Control .078 
Fluency 
 
.078 
Dementia 
MCI .004 
Control .000 
MCI Control .000 
Visuospatial 
 
.000 
Dementia 
MCI .259 
Control .034 
MCI Control .377 
Delayed Memory 
Dementia 
MCI .007 
Control .000 
MCI Control .001 
 
Secondary hypothesis 
It was also hypothesized that the optimal cut-off for discriminating between those who 
have a diagnosis of dementia will be lower in this sample of participants aged 75 and over than 
those suggested in the Hsieh et al. [9] original validation study.  
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Diagnostic interpretation 
Dementia vs controls 
Figure 1 shows the ROC curve for M-ACE total score differentiating dementia from 
healthy controls. The AUC of 0.975 (95% CI 0.871 – 0.999) indicates excellent diagnostic 
accuracy. The optimal cut-off score was defined as that with the maximal classification 
accuracy. See Table 3 for sensitivity, specificity, PPV, NPV, Youden index and likelihood 
ratios for all potential cut-offs.   
 
Figure 1. ROC curve of the M-ACE detecting dementia (dementia vs controls) 
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Table 3. Sensitivity, specificity, positive and negative predictive values (PPV, NPV), Youden index 
and likelihood ratios (LR) for the M-ACE at different cut-offs for dementia. 
Cut-off Sensitivity Specificity PPV(NPV) 
Youden 
Index 
LR+ LR- 
       
≤29 100 0.11 17.65 (0) 0.11 1.13 0 
≤28 100 0.17 0.63 (100) 0.17 1.21 0 
≤27 100 0.35 0.68 (100) 0.35 1.55 0 
≤26 0.95 0.47 0.71 (0.88) 0.42 1.81 0.09 
≤25 0.95 0.70 0.82 (0.92) 0.65 3.26 0.06 
≤24 0.95 0.76 0.85 (0.92) 0.71 4.07 0.05 
≤23 0.95 0.94 0.95 (0.94) 0.89 16.29 0.04 
≤22 0.95 0.94 0.95 (0.94) 0.89 16.29 0.04 
≤21 0.95 1 100 (0.94) 0.95 Infinity 0.04 
≤20 0.95 1 100 (0.94) 0.95 Infinity 0.04 
≤19 0.83 1 100 (0.80) 0.75 Infinity 0.17 
       
 
Statistics characterising the diagnostic performance for the existing M-ACE cut-offs 
and an optimal alternative cut-off are presented in Table 3. For the higher published cut-off 
(≤25/30), sensitivity was excellent (0.95) however specificity was much poorer (.70). The 
lower published cut-off (≤21/30) demonstrated excellent sensitivity (0.95) and specificity (1) 
and is the optimal cut-off from the data in the current study as it also had the equal highest 
Youden index (published and proposed cut-offs are highlighted in bold). ≤20/30 had an equally 
high Youden index however ≤21/30 has been chosen here as the maximum cut-off as it is 
preferred to err on the side of capturing impairment where it is potentially present. It should be 
noted that one participant in the dementia group scored 27/30 whilst the remaining participants 
all had scores of ≤20/30. The participant who scored 27/30 had the highest years of education 
of any of the dementia group (17 years). Data in Table 4 illustrate how disease prevalence level 
impacts the diagnostic performance of the lower cut-off of ≤21/30. 
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Table 4. PPV and NPV for different prevalence rates for a lower potential cut-off score 
 
M-ACE cut-off PPV/NPV at specified prevalence 
 5% 10% 20% 40% 50% 60% 
       
≤21 PPV 1 1 1 1 1 1 
       NPV 0.99 0.99 0.99 0.97 0.95 0.93 
       
 
Dementia & MCI vs controls 
The data were also analysed to examine the diagnostic performance of the M-ACE in 
distinguishing between all impaired participants (dementia and MCI) and healthy controls. 
Figure 2 shows the ROC curve for M-ACE total score differentiating all impaired participants 
(dementia and MCI) from healthy controls. The AUC of 0.941 (95% CI 0.886 – 0.997) 
indicates excellent diagnostic accuracy. Again, the optimal cut-off score was defined as that 
with the maximal classification accuracy. 
 
Figure 2. ROC curve of the M-ACE detecting dementia and MCI (dementia & MCI vs controls). 
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For the higher published cut-off (≤25/30), sensitivity was high (0.92) however 
specificity was poorer, (0.70). The lower published cut-off (≤21/30) demonstrated poor 
sensitivity (0.78) but excellent specificity (1). The optimal cut-off for distinguishing between 
the impaired participants (dementia and MCI) and the healthy controls in this sample was 
≤23/30 as this had the highest sensitivity, specificity and the highest Youden index (published 
and proposed cut-offs highlighted in bold). See Table 5 for sensitivity, specificity, Youden 
index, PPV, NPV, LR+ and LR- for all potential cut-offs.   
 
Table 5. Sensitivity, specificity, positive and negative predictive values (PPV, NPV) and likelihood 
ratios (LR) for the M-ACE at different cut-offs for dementia. 
Cut-off Sensitivity Specificity PPV(NPV) 
Youden 
Index 
LR+ LR- 
       
≤29 1 0.11 0.61 (1) 0.11 1.13 0.00 
≤28 1 0.17 0.63 (1) 0.17 1.21 0.00 
≤27 1 0.35 0.68 (1) 0.35 1.55 0.00 
≤26 0.95 0.46 0.81 (0.80) 0.41 1.80 0.10 
≤25 0.92 0.70 0.88 (0.80) 0.62 3.15 0.10 
≤24 0.87 0.76 0.90 (0.72) 0.63 3.73 0.16 
≤23 0.85 0.94 0.97 (0.72) 0.79 14.10 0.18 
≤22 0.82 0.94 0.97 (0.69) 0.76 14.10 0.18 
≤21 0.78 1 1 (0.65) 0.78 Infinity 0.22 
≤20 0.73 1 1 (0.60) 0.73 Infinity 0.27 
       
 
Table 6 highlights how disease prevalence impacts the diagnostic accuracy of the 
alternative cut-off. As disease prevalence increases, the NPV decreases gradually whilst the 
PPV only falls below chance levels when prevalence reaches 5%. 
Table 6. PPV and NPV for different prevalence rates for a potential alternative cut-off score. 
M-ACE cut-off PPV/NPV at specified prevalence 
 5% 10% 20% 40% 50% 60% 
       
≤23 PPV 0.43 0.61 0.78 0.90 0.93 0.95 
     NPV 0.99 0.98 0.96 0.90 0.86 0.81 
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Dementia vs MCI 
The data were also analysed to examine the diagnostic performance of the M-ACE in 
distinguishing between the dementia and MCI groups. Figure 3 shows the ROC curve for M-
ACE total score differentiating dementia participants from those with a diagnosis of MCI. The 
AUC of 0.849 (95% CI 0.731 – 0.967) indicates excellent diagnostic accuracy. The optimal 
cut-off score was defined as that with the maximal classification accuracy. 
 
Figure 3. ROC curve of the M-ACE detecting dementia (dementia vs MCI) 
 
For the higher published cut-off (≤25/30), sensitivity was high (0.95) however 
specificity was poor (0.11). The lower published cut-off (≤21/30) demonstrated poor sensitivity 
(0.47) but excellent specificity (0.95). The optimal cut-off for distinguishing between the 
participants with a dementia and those with an MCI in this sample was ≤15/30 as this had the 
highest sensitivity, specificity and the highest Youden index. It should be noted however that 
the sensitivity for ≤15/30 was poor (0.62), therefore the test is not particularly good at 
distinguishing between MCI and dementia. (See Table 7 for sensitivity, specificity, PPV, NPV, 
 67 
 
 
Youden index LR+ and LR- for all potential cut-offs (with published and proposed cut-offs 
highlighted in bold).  
 
Table 7. Sensitivity, specificity, positive and negative predictive values (PPV, NPV) and likelihood 
ratios (LR) for the M-ACE at different cut-offs for dementia. 
Cut-off Sensitivity Specificity PPV(NPV) 
Youden 
Index 
LR+ LR- 
       ≤25 0.95 0.11 0.60 (0.66) 0.06 1.09 0.35 
≤24 0.95 0.23 0.63 (0.80) 0.18 1.25 0.18 
≤23 0.95 0.29 0.65 (0.83) 0.24 1.36 0.14 
≤22 0.95 0.35 0.67 (0.85) 0.30 1.48 0.12 
≤21 0.95 0.47 0.71 (0.88) 0.42 1.81 0.089 
≤20 0.95 0.58 0.76 (0.90) 0.53 2.33 0.071 
≤19 0.83 0.64 0.76 (0.73) 0.47 2.36 0.26 
≤18 0.75 0.64 0.75 (0.64) 0.39 2.12 0.39 
≤17 0.66 0.76 0.80 (0.61) 0.42 2.83 0.44 
≤16 0.66 0.82 0.84 (0.63) 0.48 3.78 0.40 
≤15 0.62 0.94 0.93 (0.64) 0.56 10.62 0.40 
≤14 0.50 1 1 (0.58) 0.50 Infinity 0.50 
       
 
Table 8 shows how disease prevalence impacts the diagnostic accuracy of the M-ACE 
using the proposed alternative cut-off. As disease prevalence increases, NPV decreases. PPV 
falls to almost chance levels when it reaches 10% prevalence.  
 
Table 8. PPV and NPV for different prevalence rates for a lower potential cut-off score. 
M-ACE cut-off PPV/NPV at specified prevalence 
 5% 10% 20% 40% 50% 60% 
       
≤15 PPV 0.35 0.54 0.72 0.87 0.91 0.94 
     NPV 0.97 0.95 0.90 0.79 0.71 0.62 
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Discussion 
This study adds to the literature regarding the diagnostic utility of the Mini-
Addenbrooke’s Cognitive Examination. In particular, it extends our knowledge of how we 
should expect over 75s with dementia, MCI or no cognitive impairment in a UK population to 
perform on this cognitive screen. This study shows that the M-ACE can accurately distinguish 
between patients with dementia and controls. For the diagnosis of dementia in a UK sample of 
75-89 year olds, the results of the study also suggest that the higher published cut-off of ≤25/30 
has unacceptably low specificity (0.70). The lower published cut-off (21/30) performs much 
better at differentiating dementia from controls (sensitivity 0.95, specificity 1). To distinguish 
between all impaired participants (those with dementia and MCI) and healthy controls, the 
maximal cut-off was found to be ≤23/30, with a sensitivity of 0.85 and specificity of 0.94. 
When differentiating between dementia and MCI, a potential cut-off of ≤15/30 was revealed 
to yield poor sensitivity (0.62) but excellent specificity (0.94).  
 
Although the planned sample size was not achieved, the study had a high level of 
statistical power. Large effect sizes were found for all groups (1.4 for dementia/MCI, 1.9 for 
MCI/control and 3.3 for dementia/control.)  
 
Additionally it should be noted that one dementia participant with 17 years education, 
achieved an unusually high score on the M-ACE (27/30). It is a reminder that clinicians must 
bear in mind a participant’s education level when evaluating the results of any cognitive screen. 
Implications for Clinical Practice 
The results of the current study show that the M-ACE has excellent diagnostic accuracy 
in distinguishing between dementia and healthy controls however a lower cut-off of ≤21/30 
may have greater accuracy with those in the 75+ age group. The 
M-ACE also showed good ability to distinguish between participants with any cognitive 
impairment (MCI/dementia) from healthy controls however as one might expect there was far 
more overlap between scores for these groups highlighting the importance of not relying on 
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cognitive test scores from a brief screening tool but rather to use scores as a guide when 
deciding on whether to carry out more detailed neuropsychological assessment. 
 
 
Limitations of the study 
This study has some limitations. The key limitation of this study is that the procedure 
involved comparing clearly defined patients with healthy controls which does not reflect the 
challenge facing clinicians in clinical practice. The ideal method, such as that employed in Jubb 
& Evans (2015) [14], would be to test consecutive referrals to a memory clinic. This would 
ensure that the researcher is truly blind to the participant’s condition (given that it would be 
unknown at this point) and it would also reflect the population seen in memory clinics. The 
current study included many more female than male participants and not every participant was 
recruited with an age-matched control. This proved difficult mainly because the current study 
sought to recruit older adults in an age range where many were widowed.  
Another limitation of this study is that whilst dementia and MCI participant’s ACE-III 
scores were collected, the majority of them had been carried out more than six months before 
data collection. This means that it was not possible to explore the relationship between M-ACE 
and ACE-III score.  
Research which seeks to recruit older adults also faces challenges such as older people 
being less mobile and therefore less likely to be able to attend clinic visits. This study involved 
visiting the majority of participants at their homes which placed significant time constraints on 
data collection for the current study. Participants with a diagnosis of MCI are particularly 
difficult to recruit. The principal reason for this is that patients diagnosed with MCI are often 
discharged back to the care of their GP. Previous research has noted the challenges of recruiting 
for studies which involve participants with MCI and dementia [21].   
Implications for Further Research  
Future research should seek to further validate the M-ACE in a UK sample by recruiting 
a larger sample with an extended age range. It will also be necessary to explore the relationship 
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between M-ACE and ACE-III scores. To do this, it would be ideal to recruit consecutive 
referrals from a UK memory clinic such as the procedure used in Jubb & Evans (2015) [14]. 
This would allow for better recruitment of dementia, MCI and age/education-matched controls 
and would be highly representative of the population seen in clinical practice. 
 
Conclusions 
This study further validated the M-ACE in a UK sample of older adults aged 75-89. It 
confirmed that the M-ACE has excellent diagnostic accuracy in detecting dementia and mild 
cognitive impairment in clinical practice. As with the ACE-R and ACE-III, it may be necessary 
to consider cut-offs lower than those specified in the original M-ACE validation paper. 
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Systematic Review Appendices 
 
Appendix 1.1: Search terms. 
 
Mesh term (“malingering’)  
OR  
Keywords (“test* of effort” OR “symptom validity test*” OR “symptom validity” OR “effort 
test*” OR “validity test*” OR “performance validity”) 
AND 
Mesh term (dementia) 
OR 
Mesh term (MCI) OR (mild cognitive impairment)  
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Appendix 1.2: Quality Rating Checklist. 
 
Quality Rating Checklist 
 
Study Reference:     _____________________ 
 
2 Information well-presented and in detail. 
1 Information presented but not in adequate detail. 
0 Information not present. 
 
Items Score 
Abstract and Introduction  
Abstract provides a structured summary of study design, methods, 
results, and conclusions. 
 
Introduction clearly states the scientific and clinical background, 
including intended use and clinical role of index test and clearly 
states the research objectives and hypotheses. 
 
Total for abstract and introduction /4 
Methodology  
On what basis potentially eligible participants were identified 
(such as symptoms, results from previous tests, inclusion in 
registry) 
 
Selection criteria are clearly described (inclusion and exclusion)  
Describes the number, training and expertise of the persons 
executing and reading the index tests and the reference standard 
 
Whether data collection was planned before the index test and 
reference standard were performed (prospective study) or after 
(retrospective study) 
 
Index test, in sufficient detail to allow replication  
Reference standard in sufficient detail to allow replication  
Is the reference standard likely to classify the condition correctly  
The reference standard was independent of the index test (i.e. the 
index test did not form part of the reference standard). 
 
Reference standard results are interpreted without knowledge of 
the results of the index test 
 
Total for methodology /18 
Results and Discussion  
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An explanation is provided for withdrawals from the study  
Methods for estimating or comparing measures of diagnostic 
accuracy seem reasonable 
 
Discussion: Study limitations, including sources of potential bias, 
statistical uncertainty, and generalizability 
 
Total for results and discussion /6 
Score overall /28 
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Appendix 1.3: Crowe Critical Appraisal Tool (CCAT) Version 1.4 (2013). 
 
 78 
 
 
 
 79 
 
 
Major Research Project Appendices 
 
Appendix 2.1: Author Guidelines 
 
Submission 
 
Two types of manuscripts will be considered and should be submitted online:  
Online Manuscript 
Submission  
 
1. Original Research Articles. An Abstract, Introduction, Materials and Methods, 
Results, and Discussion sections are required. 
 
2. Review Articles in which a specific field is reviewed through an exhaustive 
literature survey. An Abstract is required and should be divided into Background, 
Summary and Key Messages. Review Articles should consist of a maximum of 4,000 
words. 
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Names, postal and e-mail addresses of 6 experts in the appropriate area of research 
should accompany each manuscript. Referees suggested should not be from the 
same institution or be research collaborators of the author(s).  
 
Should you experience any problems with your submission, please contact: 
 
Prof. V. Chan-Palay 
S. Karger AG 
Editorial Office 'Dementia and Geriatric Cognitive Disorders' 
P.O. Box 
CH-4009 Basel (Switzerland) 
Tel. +41 61 306 1437 
Fax +41 61 306 1434 
E-Mail dem@karger.com 
 
Conditions 
 
All manuscripts are subject to editorial review.  
 
Manuscripts are received with the explicit understanding that they are not under 
simultaneous consideration by any other publication. Submission of an article for 
publication implies transfer of the copyright from the author to the publisher upon 
acceptance. Accepted papers become the permanent property of ‘Dementia and 
Geriatric Cognitive Disorders’ and may not be reproduced by any means, in whole or 
in part, without the written consent of the publisher.  
 
It is the author's responsibility to obtain permission to reproduce illustrations, 
tables, etc. from other publications.  
 
The manuscripts should be accompanied by a statement by the submitting author 
certifying that all the authors have read the papers and have agreed to be listed as 
authors. A similar statement should be appended for the names of colleagues who 
are acknowledged in footnotes as having contributed to or criticized the paper.  
 
For papers involving human subjects, adequate documentation should be provided to 
certify that appropriate ethical safeguards and protocols have been followed. Animal 
experiments should include a clear description of the method of anesthesia and 
killing. 
Conflicts of Interest 
 
Authors are required to disclose any sponsorship or funding arrangements relating to 
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their research and all authors should disclose any possible conflicts of interest. 
Conflict of interest statements will be published at the end of the article. 
 
Ethics 
 
Published research must comply with the guidelines for human studies and animal 
welfare regulations. Authors should state that subjects have given their informed 
consent and that the study protocol has been approved by the institute's committee 
on human research. Further, they should also state that animal experiments conform 
to institutional standards. 
 
Peer-Review Policy 
 
Dementia and Geriatric Cognitive Disorders is a peer-reviewed journal that uses a 
single-blind peer-review. Our aim is to provide authors with fast and constructive 
feedback regarding their submitted manuscript. The Editor-in-Chief and the 
international editorial board ensure a thorough and fair peer-review and the highest 
scientific publishing standards. Editors guide the peer-review process for papers in 
their areas of expertise. They select reviewers and make the decision whether to 
accept/reject or send a manuscript for revision after at least two review reports are 
received, and then a further decision to accept/reject or request further revisions 
following author revisions. Reviewers must have a recent publication record in the 
area of the submission, must not have published with the authors in the previous 
three years, and must not be from the same institution as the authors. The Editor-
in-Chief is responsible to maintain high-quality peer-review of papers submitted to 
the journal. 
 
Plagiarism Policy 
 
Whether intentional or not, plagiarism is a serious violation. We define plagiarism as 
a case in which a paper reproduces another work with at least 25% similarity and 
without citation. 
If evidence of plagiarism is found before/after acceptance or after publication of the 
paper, the author will be offered a chance for rebuttal. If the arguments are not 
found to be satisfactory, the manuscript will be retracted and the author sanctioned 
from publishing papers for a period to be determined by the responsible Editor(s). 
 
Arrangement 
 
All pages should be consecutively beginning numbered with the title page, then the 
text, acknowledgements, references and legends to figures. 
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Title page: The first page of each paper should indicate the title, the authors' 
names, the institute where the work was conducted, and a short title for use as 
running head. 
NB: Authors wishing to preserve the phonetic meaning of diacritics (PubMed reduces 
diacritics to their root characters) must spell their names accordingly when 
submitting manuscripts (e.g. Müller should be Mueller). 
 
Title: Shorter titles are easier to read. To facilitate electronic retrieval of your 
paper, titles should be kept to the point and contain only relevant information. 
 
Full address: The exact postal address of the corresponding author complete with 
postal code must be given at the bottom of the title page. Please also supply a 
phone number, as well as e-mail address. 
 
Key words: Please supply 3–10 key words in English that reflect the content of the 
paper. Please use key words as found in the headings of Index Medicus or MeSH 
database, avoid terms already present in your title and be specific. 
 
Abstracts of Review Articles: Should be divided into the following subsections: 
Background, Summary and Key Messages. The Background should provide a brief 
clinical context for the review and is followed by the Summary, which should include 
a concise description of the main topics covered in the text. The Key Messages 
encapsulate the main conclusions of the review. 
 
Abstracts of Original Research Articles: The first page of the text should include 
an abstract of up to 10 lines. It should be structured as follows: 
   Background/Aims: What is the major problem that prompted the study? 
   Methods: How was the study carried out? 
   Results: Most important findings? 
   Conclusion: Most important conclusion? 
 
Footnotes: Avoid footnotes. 
 
Abbreviations: Abbreviations should not be used excessively in the text. Only 
standard abbreviations should be used. Nonstandard abbreviations of terms that are 
used frequently in the text should be explained by the term written out completely 
and followed immediately by the abbreviation in parentheses, for example: ‘increase 
in norepinephrine (NE) content ...’. 
 
Tables and illustrations: : Tables are part of the text. Place them at the end of the 
text file. Illustration data must be stored as separate files. Do not integrate figures 
into the text. Electronically submitted b/w half-tone and color illustrations must have 
a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. 
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Color Illustrations 
 
Online edition: Color illustrations are reproduced free of charge. In the print 
version, the illustrations are reproduced in black and white. Please avoid referring to 
the colors in the text and figure legends.  
 
Print edition: Up to 6 color illustrations per page can be integrated within the text 
at CHF 960.00 per page. 
 
References 
 
In the text identify references by Arabic numerals [in square brackets]. Material 
submitted for publication but not yet accepted should be noted as ‘unpublished data’ 
and not be included in the reference list. The list of references should include only 
those publications which are cited in the text. Do not alphabetize; number 
references in the order in which they are first mentioned in the text. The surnames 
of the authors followed by initials should be given. There should be no punctuation 
other than a comma to separate the authors. Preferably, please cite all authors. 
Abbreviate journal names according to the Index Medicus system. Also see 
International Committee of Medical Journal Editors: Uniform requirements for 
manuscripts submitted to biomedical journals (www.icmje.org). 
 
 
 
Examples 
 
(a) Papers published in periodicals:  
Allain H, Bentue-Ferrer D, Tribut O, Pinel J-F: Drugs and 
vascular dementia. Dement Geriatr Cogn Disord 2003;16:1–
6. 
 
(b) Papers published only with DOI numbers:  
Theoharides TC, Boucher W, Spear K: Serum interleukin-6 
reflects disease severity and osteoporosis in mastocytosis 
patients. Int Arch Allergy Immunol DOI: 
10.1159/000063858. 
 
(c) Monographs:  
Matthews DE, Farewell VT: Using and Understanding Medical 
Statistics,  
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ed 3, revised. Basel, Karger, 1996. 
 
(d) Edited books: 
Tarou LR, Bloomsmith MA, Hoff MP, Erwin JM, Maple TL: The 
behavior of aged great apes; in Erwin JM, Hof PR (eds): 
Aging in Nonhuman Primates. Interdiscipl Top Gerontol. 
Basel, Karger, 2002, vol 31, pp 209–231. 
 
Reference Management Software: Use of EndNote is recommended for easy 
management and formatting of citations and reference lists. 
 
Digital Object Identifier (DOI) 
 
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number 
will be printed on the title page of each article. DOIs can be useful in the future for 
identifying and citing articles published online without volume or issue information. 
More information can be found at www.doi.org 
 
Supplementary Material 
 
Multimedia files and other supplementary files, directly relevant but not essential to 
the conclusions of a paper, enhance the online version of a publication and increase 
its visibility on the web. These files will undergo editorial review. The Editors reserve 
the right to limit the scope and length of the supplementary material. Multimedia 
and supplementary material should meet production quality standards for publication 
without the need for any modification or editing. Files should not exceed 10 MB in 
size. Figures and tables need to have titles and legends, and all files should be 
supplied separately and labeled clearly. All supplementary material should be 
referred to in the main text. A DOI number will be assigned to supplementary 
material and it will be hosted online at https://karger.figshare.com under a CC BY 
license. Authors will be charged a processing fee of CHF 250.00 for supplementary 
material. 
 
 
Self-Archiving/Green Open Access 
 
Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-
prints (i.e. accepted manuscript after peer review but before production) on their 
personal or their institution’s internal website. In addition, authors may post their 
accepted manuscripts in public Open Access repositories and scientific networks 
(e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of 
the final version of their article. For all self-archiving, the posted manuscripts must: 
 Be used for noncommercial purposes only 
 Be linked to the final version on www.karger.com 
 85 
 
 
 Include the following statement: 
‘This is the peer-reviewed but unedited manuscript version of the following article: 
[insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 
10.1159/000361001)]. The final, published version is available at 
http://www.karger.com/?doi=[insert DOI number].’ 
It is the author’s responsibility to fulfill these requirements. 
For papers published online first with a DOI number only, full citation details must 
be added as soon as the paper is published in its final version. This is important to 
ensure that citations can be credited to the article. 
Manuscripts to be archived in PubMed Central due to funding requirements will be 
submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)]. 
For self-archiving Author's ChoiceTM (Gold Open Access) articles, see Author's 
ChoiceTM. 
 
Author's ChoiceTM 
 
Karger’s Author's ChoiceTM service broadens the reach of your article and gives all 
users worldwide free and full access for reading, downloading and printing at 
www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which 
is a permissible cost in grant allocation. More information can be found at 
www.karger.com/authors_choice. 
The final, published version of the article may be posted at any time and in any 
repository or on other websites, in accordance with the relevant Creative Commons 
license. Reposted Open Access articles must: 
 Follow the terms of the relevant Creative Commons license 
 Be linked to the final version on www.karger.com 
 Include the following statement: 
‘The final, published version of this article is available at 
http://www.karger.com/?doi=[insert DOI number].’ 
It is the author’s responsibility to fulfil these requirements. 
For papers published online first with a DOI number only, full citation details must 
be added as soon as the paper is published in its final version. This is important to 
ensure that citations can be credited to the article. 
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Funding Organizations (NIH etc.) 
 
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that 
accepted, peer-reviewed manuscripts are archived in its digital database, PubMed 
Central (PMC), within 12 months of the official publication date. As a service to 
authors, Karger submits NIH-funded articles to PMC on behalf of the authors 
immediately upon publication. The NIH assigns a PMCID within approximately 1 
month and the manuscript will appear in PMC after a 12-month embargo. For 
authors making their paper Open Access through Author's ChoiceTM, the embargo will 
be overridden, thereby accelerating the accessibility of the article. Karger also 
complies with other funders’ requirements (including Wellcome Trust and RCUK) for 
submission to PMC. 
Authors should include information on their grant in the Acknowledgements section 
of their papers. 
 
 
Page Charges 
 
There are no page charges for papers of 3 or fewer printed pages (including tables, 
illustrations and references). Each additional complete or partial page is charged to 
the author at CHF 325.00. The allotted size of a paper is equal to approx. 8 
manuscript pages (including tables, illustrations and references). 
 
 
Proofs 
 
Unless otherwise indicated, proofs are sent to the corresponding-named author and 
should be returned with the least possible delay. Alterations other than the 
correction of printer's errors are charged to the author. 
 
Reprints 
 
Order forms and a price list are sent with the proofs. Orders submitted after the 
issue is printed are subject to considerably higher prices. 
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Appendix 2.2: Major Research Project proposal 
 
Major Research Project Proposal 
An investigation of the utility of the Mini Addenbrooke’s Cognitive Examination (M-
ACE) for the early detection of dementia and mild cognitive impairment in people aged 
75 and over. 
 
Matriculation number: 2109099 
Version number: 3 
Word count: 4054 
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Abstract 
Background: Cognitive screening tools are crucial for the accurate detection and differential 
diagnosis of dementias.  Accurate and timely assessment is important for accessing 
appropriate support and treatment options and for estimating the likely course of the disease. 
There are a range of screening tools available to clinicians however shorter cognitive tools 
are particularly useful in busy clinical settings. The Mini Mental State Examination (MMSE; 
Folstein et al, 1975) is one the most widely used screens. Despite being recommended by 
national guidelines SIGN and NICE, the MMSE has several shortcomings. In 2014, Hsieh et 
al introduced the Mini Addenbrooke's Cognitive Examination (M-ACE, a shortened version 
of the widely used Addenbrooke's Cognitive Examination III - ACE III), a possible 
alternative to the MMSE. The current study aims to further the validation of the M-ACE by 
exploring its use in a UK clinical setting with individuals aged 75 and over. 
 
Aims: The primary aim of this study is to investigate if the M-ACE can be used with people 
aged 75 and over to distinguish between those who do and do not have a diagnosis of 
dementia. 
The secondary aim is to investigate whether the cut-off scores recommended by Hsieh et al 
(2014) in the original validation study for the M-ACE are optimal. 
 
Methods: Participants will be approximately 66 individuals aged 75 and over who will have 
their cognitive function assessed using the M-ACE. There will be approximately 44 
participants who will be patients referred to Community Mental Health Teams (CMHTs) (22 
with a diagnosis of dementia, 22 with mild cognitive impairment (MCI)) for investigation of 
memory problems whilst 22 individuals will be healthy controls (the spouses/relatives/carers 
of the referred patients).  
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Applications: This study will examine if the M-ACE is sensitive and specific to dementia 
and MCI in people aged 75 and over. It also aims to investigate if the existing published cut-
off scores are accurate for use in people aged 75+ in a UK sample. This study is intended to 
be of use to health care professionals as they are increasingly called on to investigate memory 
problems in those aged 75+ and as there is more demand for shorter cognitive screens in busy 
clinical settings. 
 
Background Information and Rationale: 
Background: 
Dementia describes a set of symptoms that may include memory loss and difficulties with 
thinking, problem-solving or language. In 2013, there were an estimated 44.4 million people 
with dementia making it one of the foremost public health challenges of our time 
(Alzheimer’s disease International). As of 2015, there are an estimated 850,000 people living 
with dementia in the UK. Although diagnosis rates have improved in recent years, it is 
estimated that there are still approximately a third of those with dementia in Scotland who do 
not have a diagnosis (Scotland’s National Dementia Strategy, 2013-2016). It has been 
recognised that although dementia has a profound impact on the individual and their family, a 
timely and accurate diagnosis can lead to better support, can enable people to maintain a good 
quality of life at home for as long as possible and can also empower them to make their own 
choices about their future care (World Alzheimer Report, 2011). 
 
In order to provide appropriate support to individuals with dementia, it is first necessary to be 
able to make an accurate diagnosis. Cognitive screening tools are an important part of 
dementia assessment. These tools inform whether an individual’s cognitive difficulties fall 
within an expected range for their age or whether there is a need for further investigation such 
as neuroimaging or neuropsychological assessment. Cognitive screening tools can also 
inform differential diagnosis between different types of dementia or other conditions which 
can cause cognitive impairment.  
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One of the most popular cognitive screening tools is the Mini Mental State Examination 
(MMSE; Folstein et al, 1975) which has been used worldwide to detect for dementia for the 
past three decades. The MMSE is a 30-point questionnaire that takes around 5-10 minutes to 
administer and is recommended by national guidelines (SIGN 86 and NICE). It is often used 
to track changes in a person’s cognitive function which helps to either aid a diagnosis of 
dementia, or if already diagnosed, helps to determine what stage the person is at. However, 
despite its popularity the MMSE has been found to have several weaknesses including poor 
sensitivity to mild cognitive impairment and it is also prone to ceiling and floor effects 
(Mitchell, 2009). The test also relies heavily on verbal items which is problematic when using 
the test with individuals with poor language skills and/ or low education (Lopez et al, 2005). 
A further key disadvantage to using the MMSE is a financial one: the test has been placed 
under copyright since 2001, incurring a cost of 80p every time it is used. This clearly has 
huge financial implications for healthcare providers such as the National Health Service who 
face either continuing to pay thousands of pounds for continued access to the MMSE or 
finding an alternative resource. 
 
Due to an increasing awareness of the insufficient assessment provided by the MMSE, other 
cognitive tests have been developed which aim to be extended versions of the test. One of the 
most popular of these extended tests is the Addenbrooke’s Cognitive Assessment (ACE) 
which was introduced in 2000 as a brief cognitive screening tool which incorporated the 
MMSE but which also explored important areas not covered by it, such as visuospatial skills, 
frontal-executive function and more complex language assessment. The ACE is a 100-point 
test battery which takes approximately 15-20 minutes to administer. The validation study of 
the first version of the ACE indeed showed that it was superior to the MMSE in both 
detecting dementia and differentiating between Alzheimer’s disease and fronto-temporal 
dementia (Mathuranath et al, 2000). The ACE which is now in its third version (the ACE-III) 
is recommended by both NICE and SIGN guidelines as an extended screening to be used 
when clinicians require a more detailed picture of a patient’s cognitive function. Despite the 
ACE-III being a robust screening tool, the time that it takes to complete it means that it is not 
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always a viable option in busy clinics. Whilst clinicians should aim to complete as 
comprehensive an initial cognitive screen as possible, in practice this is not always viable 
meaning that clinicians need to have the option of a very brief measure for such occasions. 
 
The focus of the current study concerns one such new brief screening tool: the Mini 
Addenbrooke’s Cognitive Examination (M-ACE) which is a shortened version of the ACE. 
The M-ACE was devised and validated by Hsieh et al in 2014 as it was felt that the ACE-III 
which takes 15-20 minutes to administer is ‘outwith the scope of many clinical settings’. 
(Hsieh et al, 2014). The M-ACE takes under 5 minutes to administer and contains 5 items 
assessing orientation, memory, animal fluency and clock drawing. It is scored out of 30 with 
two cut-offs recommended: (1) 25/30 and (2) 21/30.  First, the higher cut-off of 25/30 has 
both high sensitivity and specificity and is at least 5 times more likely to have come from a 
patient with dementia than without. A lower cut-off of 21/30, by contrast, is almost certainly 
diagnostic of a dementia syndrome regardless of the prevalence rate. The M-ACE validation 
study showed that the M-ACE is more sensitive than the MMSE and is less likely to have 
ceiling effects. There is a need to further explore the M-ACE and its potential as a brief 
screening tool which is the purpose of the current study. 
 
The initial validation study for the M-ACE was conducted in Australia, therefore there is a 
requirement for the utility of the M-ACE to be investigated in a UK clinical setting. The 
focus of the current study will be on individuals aged 75 and over who are referred to a 
CMHT for memory problems. A control group of healthy individuals with no history of 
memory problems will also be aged 75+. There are several reasons for focusing on this age 
group. One reason is that age is a key risk factor for developing a dementia. The prevalence 
of dementia in people aged 70-74 is 3% which rises to 6% for 75-79 olds and 11.1% for 80-
84 year olds (Dementia UK Update, Alzheimer’s Society, 2014). 
 
Further, with increased improvements in healthcare there is going to be a significant increase 
in the proportion of people aged 75+ in the population. By 2031 the number of people aged 
 92 
 
 
75+ is projected to increase by 75% (All Our Futures, Planning for Scotland with an Ageing 
Population, Scottish Executive, 2007). In Scotland alone this figure is projected to increase to 
94,000 by 2017 and 108,000 by 2022; with incidence of 9,400 and 10,800 respectively. This 
represents a 12% increase by 2017 and a 29% increase by 2022. (Delivering Integrated 
Dementia Care: The 8 Pillars Model of Community Support, Alzheimer’s Scotland). This 
creates a challenge for our health and social care services that will increasingly be called on 
to meet the needs of this population. 
 
A third reason for this focus comes from a limitation of the original M-ACE validation study 
by Hsieh et al (2014). This study was limited to comparing patients with controls in the age 
range 61-74. 
 
Furthermore, as people get older, they may be more suited to a shorter cognitive test as they 
may have more visual, auditory or concentration difficulties than younger patients. 
 
There is also a need to investigate the optimal cut-offs for the M-ACE for discriminating 
between those who have a diagnosis of dementia in people aged 75+. A recent study found 
that the optimal cut-offs for the ACE-III for people over the age of 75 in a UK clinical sample 
were lower than those recommended in the ACE-III validation study (Jubb et al, 2015). 
 
Aims: 
1. The primary aim of this study is to investigate if the M-ACE can be used with people 
aged 75+ to distinguish between those who do and do not have a diagnosis of 
dementia and those who have a diagnosis of MCI. 
2. The secondary aim is to investigate whether the cut-off scores recommended by Hsieh 
et al (2014) in the original validation study for the M-ACE are optimal. 
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Hypotheses: 
Primary hypothesis: 
1. There will be a significant difference between the means of the M-ACE scores for the three 
groups of participants i.e. those who have a diagnosis of dementia, MCI or no diagnosis. The 
score on the M-ACE will enable accurate discrimination between those who have a diagnosis 
of dementia, MCI and those who have no diagnosis in those aged 75+. 
 
Secondary hypothesis: 
1. The optimal cut-off for discriminating between those who have a diagnosis of dementia 
will be lower in this sample of participants aged 75+ than those suggested in the Hsieh et al 
(2014) original validation study.  
 
Methodology: 
Participants: 
Participants will be recruited from Older Adult CMHTs in Glasgow. Participants will be 
patients aged 75+ who have been referred to the CMHT for memory problems.  
 
Service users: 
Inclusion criteria:  
5. All participants must be aged 75 and over. 
6. All participants must be able to give informed consent. 
7. Have English as their first language. 
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Exclusion criteria: there will be minimal patient exclusion criteria since the study aims to 
use a sample of all patients referred to CMHTs for memory problems over the time period of 
the study. However patients in the dementia and MCI groups should: 
4. Not be experiencing cognitive impairment due to a neurological condition (e.g. due to 
head injury, alcohol-related damage, epilepsy). 
5. Have no significant hearing or vision problems which would prevent their completion 
of the M-ACE. 
6. Not have a learning disability. 
 
Control group: 
Inclusion criteria: 
1. 1. All participants must be aged 75 and over and have English as their first language. 
 
Exclusion criteria: similar exclusion criteria will exist for control group participants. 
Therefore participants in the control group should: 
2. Not have significant hearing or vision problems which would prevent their 
completion of the M-ACE. 
3. Not have a neurological condition. 
4. Not have a learning disability. 
5. Have no prior history of memory problems.  
 
Recruitment Procedure: All participants in the dementia and MCI groups will be patients 
who have been referred to the CMHT. All participants in the no diagnosis group will be 
spouses/carers of people referred to the CMHT (not just those patients who are included in 
the study). 
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Measures: 
● The Mini Addenbrooke’s Cognitive Examination (M-ACE) is the primary outcome 
measure and is free of charge to download (https://www.neura.edu.au/frontier/research/test-
downloads/). 
● Information sheet and consent form (to be drawn up by primary researcher). 
● Access to ACE-III scores from patient case files. 
● Demographic sheet to record demographic details of each participant. In order to know 
about years of education, exact age. 
 
Research Procedure: 
Dementia and MCI group participants: 
All patients referred to the CMHT for investigation of memory problems who meet the 
inclusion criteria will be approached to take part in the study. As part of usual procedure, 
patients will be visited at home and have their cognitive function assessed using the ACE-III 
by a member of the team (usually a Community Psychiatric Nurse - CPN). The CPN will 
give the patient an information sheet about the study and if they agree to take part then they 
will allow the CPN to pass on their contact details to the primary researcher. The CPN will 
make it explicit that the patient can withdraw their participation in the study at any time and 
that they will not be required to give a reason for doing so. 
 
In order to access potential participants who have a diagnosis of MCI, staff will contact 
clients who have been recently discharged from their caseload (within the past 2 months) and 
who have been given a diagnosis of MCI. The staff member who provided input to the client 
with MCI will telephone the client to ask if they are interested in participating. At present, 
clients who are given a diagnosis of MCI, are usually discharged back to the care of their GP 
within a short timeframe. 
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The primary researcher will telephone the patient to arrange a home visit. At the home visit 
the primary researcher will explain the purpose of the study, answer any questions the patient 
may have about participation in the study and they will sign a consent form. The patient will 
also be asked to complete a brief information sheet asking about age, gender and years of 
education (Appendix). The researcher will then administer the M-ACE. 
 
The scores from the ACE-III will fall into one of three possible groups: 1) the patient scores 
above the cut-off and no further investigation is necessary (unlikely outcome given that they 
have been referred for memory problems), 2) the patient scores in a borderline range (MCI), 
3) the patient scores below cut-off and is given a diagnosis of dementia. The primary 
researcher will not know the result of the ACE-III until the end of data collection.  
 
Control group participants: 
If there is a carer or relative present on the home visit and if they are aged 75+ and they do 
not meet exclusion criteria (see above), the CPN will ask if they would be interested in taking 
part in the study and will provide them with an information sheet. If the carer/relative wishes 
to take part, the CPN will pass on the contact details to the primary researcher who will 
contact the carer/relative by telephone in order to arrange a home visit to carry out the M-
ACE. At the visit the patient will fill out a brief information sheet and sign a consent form. 
 
Data Analysis and Justification of Sample Size: 
There will be two approaches to data analysis, the first being to examine group differences 
and the second is to investigate the diagnostic utility of the M-ACE. 
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The original validation study of the M-ACE (Hsieh et al, 2014) does not report an effect size 
therefore the validation study for the ACE-R informs the likely effect size for the current 
study. In the Hsieh et al (2014) study, Cohen’s d for the difference between controls and 
those with Alzheimer’s dementia was 1.84 which is a large effect size. GPower (v 3.1.9.2) 
(Faul et al, 2009) was used to calculate sample size. In order to detect a large effect size 
(Cohen's f= .40) with α = 0.05 , on a one-way ANOVA, 66 participants would be required 
across the three groups (22 in each group).  
 
Data regarding referrals to one of the CMHTs shows that they receive on average 35 new 
referrals each per month. Approximately 70% of these referrals are for memory problems 
therefore we could expect around 70 patients in a three month period from each CMHT 
which suggests the target of 66 participants (22 with dementia diagnosis, 22 with MCI and 22 
healthy controls) is feasible.  
 
Furthermore, for a test to be useful in a diagnostic sense, it needs to show good separation of 
groups (the M-ACE scores from the control, MCI and dementia groups should be as separate 
as possible).  
 
The primary hypothesis will be analysed using a one-way ANOVA to compare the means of 
the three groups. The data will be tested to check it is normally distributed. If it is found not 
to be normally distributed, the non-parametric equivalent of the one-way ANOVA, the 
Kruskal Wallis, will be used. 
 
Subsequent analysis of the diagnostic accuracy of the M-ACE scores will be operated using 
Receiver Operating Characteristic (ROC) analysis which will allow for examination of the 
sensitivity and specificity of different cut-off scores. In addition, positive predictive values 
and negative predictive values (PPV, NPV) will be calculated. 
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Demographic data (age and years of education) will be analysed across the three groups to 
examine if the groups differ significantly on these variables. If so, subsequent analysis will 
control for this effect. 
 
Settings and Equipment: 
The study will be conducted in participants’ homes. Print outs of the M-ACE will be required 
however there is no cost involved as the tool is free of charge to download. 
 
Health and Safety Issues 
Researcher Safety Issues: 
Due to the population being studied, mobility and transport difficulties are common and 
standard clinical practice involves staff conducting home visits in order to provide an 
equitable service. Therefore, permission has been granted to conduct home visits as necessary 
in order to allow people with such difficulties to still participate. All participants requiring a 
home visit will have been thoroughly risk assessed by trained staff in the community mental 
health teams. Local and national policy guidelines on health and safety and emergency 
procedures (e.g. lone working policy, fire safety) will be sought. A health and safety 
assessment form is included in Appendix 1. The researcher will use Guardian 24 when 
conducting home visits and all visits will be carried out during office working hours. 
Guardian 24 is a lone worker service which the researcher can call to record the time and 
duration of their visit. The researcher then calls this number again to record that they have 
safely left the visit. If the researcher fails to call this number they will be contacted by 
Guardian 24 to check their location. If there is still no response the system will contact the 
researcher’s clinical supervisor. 
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Participant Safety Issues: 
Risks to participants include the stress of having cognitive function assessed. There is also 
the risk that being assessed will uncover a problem with a participant’s cognitive function 
that they were not previously aware of. Making sure participants are fully informed and that 
pre-diagnostic counselling is given should limit these risks to the participant.  
 
Ethical Issues: 
Ethical permission will need to be sought and granted from Local Research Ethics Committee 
as the project involves accessing ACE-III scores from patient case files. Management 
approval will be sought from NHS Greater Glasgow and Clyde Research and Development. 
There are also ethical implications for administering the M-ACE to individuals who do not 
have a diagnosis. This will be made clear to participants through the information sheet and 
pre-diagnostic counselling.  
 
Financial Issues: 
Researcher will incur costs for travel to home visits. Participants are not remunerated for their 
participation. The study will be submitted to R&D NHS Greater Glasgow and Clyde for 
sponsorship.  The project will be funded by the University of Glasgow.  A total of £153.50 has 
been secured to cover the cost of photocopies and researcher travel expenses. 
 
Amendments: 
Following advice from the Sponsor, NHS R&D and the ethics board, amendments will be 
discussed by the research team and implemented accordingly.  Any amendments to the study 
will be submitted to R&D and ethics for further ethical consideration. 
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The researcher will aim to present the findings of the current study at relevant conferences 
and to publish the study in relevant journals. Participants will also be informed of the study 
results by a letter which will be drafted, summarising the main findings. 
 
Timetable 
April 2015 Submit research proposal to University  
Complete Ethics and R&D forms and 
submit 
May - August 2015 Making practical arrangements with local 
services. 
Processing of ethics and R&D 
 Processing of ethics and R&D proposals 
with any corrections 
September 2015– April 2016 Data collection 
May 2016 Data analysis 
June and July 2016 Write up 
July 2016 Submit for examination 
 
Practical Applications 
This study aims to determine if the Mini Addenbrooke’s Cognitive Examination (M-ACE) 
can be used with people aged 75+ to distinguish between those who do and do not have a 
diagnosis of dementia or MCI in a UK clinical population. The study also aims to provide 
guidance to clinicians about the appropriate cut-offs to be used in this context. 
 
Word count: 4054 
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Appendix 2.5: Participant information sheet – for people with a dementia or mild 
cognitive impairment. 
           
                                                              
 
                                                             
Mental Health & Wellbeing    
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow 
 
An Investigation of the Utility of the Mini Addenbrooke’s Cognitive 
Examination (M-ACE) for the Early Detection of Dementia and Mild Cognitive 
Impairment in People Aged 75 and Over 
 
Information Sheet 
[Version 3: 13/11/2015] 
I would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take 
time to read the following information carefully. If there is anything that is not clear or if you 
would like more information please contact me. All relevant contact details are at the bottom 
of this leaflet.  
 
Who is conducting the research? 
The research is being carried out by Claire McGuire (Trainee Clinical Psychologist) from the 
Institute of Mental Health and Wellbeing. I am a postgraduate student at the University of 
Glasgow and this research is being conducted as part of a Doctorate in Clinical Psychology.  
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What is the purpose of the study? 
The study aims to explore whether the Mini Addenbrooke’s Cognitive Examination (M-ACE), 
a short test of mental ability, is useful in detecting dementia in people aged 75 and over. 
 
Why have I been invited? 
You have been invited to take part in this study because you have been given a diagnosis of 
dementia or mild cognitive impairment and you are aged 75 or over. The study aims to 
explore the test with people who have a dementia and with people who do not have a 
dementia and who are aged 75 or over.  
  
Do I have to take part? 
No. It is up to you to decide. You will be asked to sign a consent form to show you have 
agreed to take part. You are free to withdraw at any time, without giving reason. If you do 
decide to withdraw from the study, this would not affect any care you are receiving. If you do 
decide to take part, we will, with your permission, let your G.P. know of your test results. This 
is standard practice in research and will not affect any care you receive from the NHS or 
your G.P. We will inform your G.P. of test results so that if you require any further 
assessment of your memory, these results can help inform the assessment. 
 
What does taking part involve? 
You will be invited to your nearest clinic or, if appropriate, the researcher can (with your 
permission) visit you at home. You will only need to attend the clinic (or receive a home visit) 
once. We are unfortunately unable to pay travel expenses. 
 
Taking part involves one short test which will assess your mental ability. You will also be 
asked for information about your age, gender, postcode and the number of years of 
education you have. The amount of time you can expect all this to take is approximately 15 
minutes.  
 
The researcher will also require access to previous ACE-III scores held within your medical 
records. 
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What happens to the information? 
Your identity and personal information will be completely confidential and known only to the 
researcher, her academic supervisor (Professor Jonathan Evans) and representatives of the 
study Sponsor, NHS Greater Glasgow & Clyde, who may look at it to make sure the study is 
being conducted correctly. The information obtained will remain confidential and stored 
within a locked filing cabinet and on a password protected computer. The data are held in 
accordance with the Data Protection Act, which means they are kept safely and cannot be 
revealed to other people, without your permission.  
 
What are the possible benefits of taking part? 
Many people find completing these sorts of tests interesting. It is hoped that by taking part 
you will be providing valuable information regarding how individuals aged 75 and over who 
are experiencing memory problems should score on the M-ACE. It is hoped that this 
information will influence further research into the use of short screening tools for detecting 
dementia. 
 
What are the possible disadvantages and risks of taking part? 
Your test results could indicate that your difficulties such as memory have become worse 
over time. In this instance, additional support can be provided by contacting your healthcare 
provider who may arrange a review or additional support measures for you. The researcher 
will be happy to help you with this if required. It will be helpful for your GP to be aware of the 
results of the tests and therefore if you give your permission we will inform your GP of your 
test results.  
 
If during the study, the researcher becomes aware that there are any risks of harm to 
yourself or other people, she will be duty-bound to pass this information on to relevant 
services, such as social work who may wish to speak with you further about this. Such risks 
include things like physical abuse and neglect. The researcher would, wherever possible, 
discuss this with you first, however would still need to pass the information on. This is 
standard practice and is designed to ensure that you and others are safe and are receiving 
the right amount of support and care.  
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given 
favourable opinion by the NHS West of Scotland Research Ethics Committee, Greater 
Glasgow and Clyde Research and Development Department and the University of Glasgow. 
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What will happen to the results of the study? 
If you would like to know of the overall results and conclusions of the study, the researcher 
can provide this information to you upon completion of the study.  
 
If you have any further questions? 
You will have a copy of the information sheet and signed consent form to keep. 
If you would like any general information about participating in research within the NHS, 
please contact: 
 
Professor Tom McMillan 
Director of Research and Professor of Clinical Neuropsychology 
Room 213 Level 2 
Mental Health and Wellbeing 
Gartnaval Royal Hospital 
Glasgow G12 0XH 
Telephone: 0141 211 0354 
 
If you would like further information about this particular research project please contact 
Claire McGuire, her academic supervisor Professor Jonathan Evans or her clinical 
supervisor Dr Stephanie Crawford: 
 
Contacts: 
Miss. Claire McGuire 
Trainee Clinical Psychologist 
Gartnavel Royal Hospital 
1055 Great Western Road 
G12 0XH 
Tel: 0141 211 3920 
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Professor Jonathan Evans 
Professor of Applied Neuropsychology 
Gartnavel Royal Hospital 
1055 Great Western Road 
G12 0XH 
Tel: 0141 211 3978 
 
Dr Stephanie Crawford 
Clinical Psychologist 
Belmont Centre 
Stobhill Hospital 
300 Balgrayhill Road 
G21 3UR 
Tel: 0141 232 6660 
 
If you have a complaint about any aspect of the study? 
If you are unhappy about any aspect of the study and wish to make a complaint, please 
contact the researcher in the first instance. The normal NHS complaint mechanisms are also 
available to you. For information on our complaints procedures or advice on how to make a 
complaint: 
 phone: 0141 201 4500 (for complaints only) 
 email: complaints@ggc.scot.nhs.uk 
 
Thank you for your time  
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Appendix 2.6: Letter of invitation – for people with a dementia or mild cognitive 
impairment. 
       
An Investigation of the Utility of the Mini Addenbrooke’s Cognitive 
Examination (M-ACE) for the Early Detection of Dementia and Mild 
Cognitive Impairment in People Aged 75 and Over 
 
My name is Claire McGuire and I am a trainee Clinical Psychologist. I would like to invite you 
to take part in a research study which is exploring whether a short test is able to accurately 
predict if a person is experiencing problems with their mental ability which may be 
associated with the early stages of dementia. 
The study aims to explore these tests with people who have a dementia or mild cognitive 
impairment and with people who do not. All participants will be adults aged 75+. 
Taking part involves short tests of attention, memory and language which will take 
approximately 5-10 minutes in total. You will be invited to your nearest clinic or, if 
appropriate, the researcher can (with your permission) visit you at home. You will only need 
to attend the clinic (or receive a home visit) once. 
It is hoped that this information will influence how NHS staff use different tests and 
information to predict a person’s general functioning when assessing someone who has 
concerns about their memory. 
If you would like further information about this study, please complete the slip below and 
hand it to your health care worker. The researcher will then be in touch to provide more 
information to help you decide if you would like to participate. 
------------------------------------------------------------------------------------------------------- 
An Investigation of the Utility of the Mini Addenbrooke’s Cognitive 
Examination (M-ACE) for the Early Detection of Dementia and Mild Cognitive 
Impairment in People Aged 75 and Over 
I would like to find out more about this study and I can be contacted on the details below by 
the researcher: 
Name: ________________________________________________________ 
Address: ______________________________________________________ 
Telephone number: ______________________________________________ 
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Appendix 2.7: Consent form – for people with a dementia or mild cognitive impairment 
                                                                  
 
Mental Health & Wellbeing 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow 
 
Participant number: 
An Investigation of the Utility of the Mini Addenbrooke’s Cognitive 
Examination (M-ACE) for the Early Detection of Dementia and Mild Cognitive 
Impairment in People Aged 75 and Over 
 
Consent Form 
Please initial box 
I confirm that I have read and understand the information sheet (a) [Version 3: 
13/11/2015] for the above study and have had the opportunity to ask questions. 
 
□ 
I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason. 
 
□ 
I agree for my G.P. to be informed of my test results. 
 
□ 
I consent for my G.P. and any other relevant health and social care professionals to be 
contacted in the event of any concerns raised about risk of harm to myself or others.                            
 
□ 
I agree that representatives of the study Sponsor, NHS Greater Glasgow and Clyde, 
may look at my information for audit purposes. 
 
□ 
If I have completed the ACE-III test (Addenbrooke’s Cognitive Examination III) in the 
last 6 months, I give permission for this result to be released and used in this study. 
 
□ 
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I agree to take part in the above study. 
 
□ 
 
Name of participant: ___________________________________   Date: ________________ 
Signature: ___________________________________________ 
 
Name of person taking consent: _________________________     Date: ________________ 
Signature: ____________________________________________ 
 
1 copy to the participant, 1 copy to the researcher 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 118 
 
 
Appendix 2.8: Participant information sheet – for controls. 
                                                         
 
Mental Health & Wellbeing    
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow 
 
An Investigation of the Utility of the Mini Addenbrooke’s Cognitive 
Examination (M-ACE) for the Early Detection of Dementia and Mild Cognitive 
Impairment in People Aged 75 and Over 
 
Information Sheet 
[Version 3: 13/11/2015] 
 
I would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take 
time to read the following information carefully. If there is anything that is not clear or if you 
would like more information please contact me. All relevant contact details are at the bottom 
of this leaflet.  
 
Who is conducting the research? 
The research is being carried out by Claire McGuire (Trainee Clinical Psychologist) from the 
Institute of Mental Health and Wellbeing.I am a postgraduate student at the University of 
Glasgow and this research is being conducted as part of a Doctorate in Clinical Psychology.  
 
What is the purpose of the study? 
The study aims to explore whether the Mini Addenbrooke’s Cognitive Examination (M-ACE), 
a short test of mental ability, is useful in detecting dementia in people aged 75 and over. 
 119 
 
 
 
Why have I been invited? 
You have been invited to take part in this study because you are an adult aged 75+ who 
does not have a diagnosis of dementia. The study aims to explore these tests with people 
who have a dementia and with people who do not have a dementia and who are aged 75 
and over. 
  
Do I have to take part? 
No. It is up to you to decide. You will be asked to sign a consent form to show you have 
agreed to take part. You are free to withdraw at any time, without giving reason. If you do 
decide to withdraw from the study, this would not affect any care you receive. If you do 
decide to take part, we will, with your permission, let your G.P. know of your test results. This 
is standard practice in research and will not affect any care you receive from the NHS or 
your G.P. We will inform your G.P. of test results so that if you require any future 
assessment of your memory, these results can help inform the assessment. 
 
What does taking part involve? 
You will be invited to your nearest clinic or, if appropriate, the researcher can (with your 
permission) visit you at home. You will only need to attend the clinic (or receive a home visit) 
once. We are unfortunately unable to pay travel expenses. 
 
Taking part involves one short test which will assess your mental ability. You will also be 
asked for information about your age, gender, postcode and the number of years of 
education you have. The amount of time you can expect all this to take is approximately 15 
minutes.  
 
What happens to the information? 
Your identity and personal information will be completely confidential and known only to the 
researcher, her academic supervisor (Professor Jonathan Evans) and representatives of the 
study Sponsor, NHS Greater Glasgow & Clyde, who may look at it to make sure the study is 
being conducted correctly. The information obtained will remain confidential and stored 
within a locked filing cabinet and on a password protected computer. The data are held in 
accordance with the Data Protection Act, which means they are kept safely and cannot be 
revealed to other people, without your permission.  
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What are the possible benefits of taking part? 
Many people find completing these sorts of tests interesting. It is hoped that by taking part 
you will be providing valuable information regarding how individuals aged 75 should score on 
the M-ACE. It is hoped that this information will influence further research into the use of 
short screening tools for detecting dementia. 
 
What are the possible disadvantages and risks of taking part? 
There is the possibility that completing these tests might raise concerns for you about some 
of your abilities, such as memory.  Whilst this test does not diagnose dementia, it can 
indicate areas which are becoming problematic. If your score on the test is lower than 
expected, with your permission we can inform your GP and you would then be able to 
discuss options for further assessment. 
 
If during the study, the researcher becomes aware that there are any risks of harm to 
yourself or other people, she will be duty-bound to pass this information on to relevant 
services, such as social work who may wish to speak with you further about this. Such risks 
include things like physical abuse and neglect. The researcher would, wherever possible, 
discuss this with you first, however would still need to pass the information on. This is 
standard practice and is designed to ensure that you and others are safe and are receiving 
the right amount of support and care.  
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given 
favourable opinion by the NHS West of Scotland Research Ethics Committee, Greater 
Glasgow and Clyde Research and Development Department and the University of Glasgow. 
 
What will happen to the results of the study? 
If you would like to know of the overall results and conclusions of the study, the researcher 
can provide this information to you upon completion of the study.  
 
If you have any further questions? 
You will have a copy of the information sheet and signed consent form to keep. If you would 
like any general information about participating in research within the NHS, please contact: 
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Professor Tom McMillan 
Director of Research and Professor of Clinical Neuropsychology 
Room 213 Level 2 
Mental Health and Wellbeing 
Gartnaval Royal Hospital 
Glasgow G12 0XH 
Telephone: 0141 211 0354 
 
If you would like further information about this particular research project please contact 
Claire McGuire or her clinical supervisor Dr Stephanie Crawford: 
 
Contacts: 
Miss Claire McGuire 
Trainee Clinical Psychologist 
Gartnavel Royal Hospital 
1055 Great Western Road 
G12 0XH 
Tel: 0141 211 3920 
 
Professor Jonathan Evans 
Professor of Applied Neuropsychology 
Gartnavel Royal Hospital 
1055 Great Western Road 
G12 0XH 
Tel: 0141 211 3978 
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Dr Stephanie Crawford 
Clinical Psychologist 
Belmont Centre 
Stobhill Hospital 
300 Balgrayhill Road 
G21 3UR 
Tel: 0141 232 6660 
 
If you have a complaint about any aspect of the study? 
If you are unhappy about any aspect of the study and wish to make a complaint, please 
contact the researcher in the first instance. The normal NHS complaint mechanisms are also 
available to you. For information on our complaints procedures or advice on how to make a 
complaint: 
 phone: 0141 201 4500 (for complaints only) 
 email: complaints@ggc.scot.nhs.uk 
 
Thank you for your time  
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Appendix 2.9: Letter of invitation – for control participants.  
                                                                           
An Investigation of the Utility of the Mini Addenbrooke’s Cognitive 
Examination (M-ACE) for the Early Detection of Dementia and Mild Cognitive 
Impairment in People Aged 75 and Over 
 
My name is Claire McGuire and I am a trainee Clinical Psychologist. I would like to invite you 
to take part in a research study which is exploring whether a short test is able to accurately 
predict if a person is experiencing problems with their mental ability which may be 
associated with the early stages of dementia 
The study aims to explore these tests with people who have a dementia or mild cognitive 
impairment and with people who do not. All participants will be adults aged 75+. 
Taking part involves short tests of attention, memory and language which will take 
approximately 5-10 minutes in total. You will be invited to your nearest clinic or, if 
appropriate, the researcher can (with your permission) visit you at home. You will only need 
to attend the clinic (or receive a home visit) once. 
It is hoped that this information will influence how NHS staff use different tests and 
information to predict a person’s general functioning when assessing someone who has 
concerns about their memory. 
If you would like further information about this study, please complete the slip below and 
hand it to your health care worker. The researcher will then be in touch to provide more 
information to help you decide if you would like to participate. 
------------------------------------------------------------------------------------------------------------ 
An Investigation of the Utility of the Mini Addenbrooke’s Cognitive 
Examination (M-ACE) for the Early Detection of Dementia and Mild Cognitive 
Impairment in People Aged 75 and Over 
I would like to find out more about this study and I can be contacted on the details below by 
the researcher: 
Name: ________________________________________________________ 
Address: _______________________________________________________ 
_____________________________________________________________ 
Telephone number: ______________________________________________ 
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Appendix 2.10: Consent form – for control participants 
                                                                  
Mental Health & Wellbeing 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow 
An Investigation of the Utility of the Mini Addenbrooke’s Cognitive 
Examination (M-ACE) for the Early Detection of Dementia and Mild Cognitive 
Impairment in People Aged 75 and Over 
 
Consent Form 
Participant number:             Please initial box 
I confirm that I have read and understand the information sheet (b) [Version 3: 13/11/2015] 
for the above study and have had the opportunity to ask questions. 
 
 
□ 
I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason. 
□ 
I agree for my G.P. to be informed of my test results. □ 
I consent for my G.P. and any other relevant health and social care professionals to be 
contacted in the event of any concerns raised about risk of harm to myself or others.                            
□ 
I agree that representatives of the study Sponsor, NHS Greater Glasgow and Clyde, may look 
at my information for audit purposes. 
□ 
I agree to take part in the above study. □ 
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Name of participant: ___________________________________    Date: ________________ 
Signature: ___________________________________________ 
 
Name of person taking consent: __________________________   Date: ________________ 
Signature:  ___________________________________________ 
 
1 copy to the participant, 1 copy to the researcher 
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Appendix 2.11: Information sheet for people with an MCI  
           
                                                               
Mental Health & Wellbeing    
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow 
 
An Investigation of the Utility of the Mini Addenbrooke’s Cognitive 
Examination (M-ACE) for the Early Detection of Dementia and Mild Cognitive 
Impairment in People Aged 75 and Over 
 
Information Sheet 
[Version 4: 31/05/2016] 
I would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take 
time to read the following information carefully. If there is anything that is not clear or if you 
would like more information please contact me. All relevant contact details are at the bottom 
of this leaflet.  
 
Who is conducting the research? 
The research is being carried out by Claire McGuire (Trainee Clinical Psychologist) from the 
Institute of Mental Health and Wellbeing. I am a postgraduate student at the University of 
Glasgow and this research is being conducted as part of a Doctorate in Clinical Psychology.  
 
What is the purpose of the study? 
The study aims to explore whether the Mini Addenbrooke’s Cognitive Examination (M-ACE), 
a short test of mental ability, is useful in detecting dementia and mild cognitive impairment in 
people aged 75 and over. 
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Why have I been invited? 
You are being invited to take part in this study because you have been given a diagnosis of 
mild cognitive impairment and you are aged 75 or over. The study aims to explore the test 
with people who have a dementia or mild cognitive impairment and with people who do not 
have either of these diagnoses and who are aged 75 or over.  
  
Do I have to take part? 
No. It is up to you to decide. The clinician who provides your care will contact you 
within the next few days to further discuss the project with you. There is also an opt-
in/opt-out sheet included with this information sheet which you can post to your 
clinician indicating if you wish to be contacted about the study. You will be asked to 
sign a consent form to show you have agreed to take part. You are free to withdraw at any 
time, without giving reason. If you do decide to withdraw from the study, this would not affect 
any care you are receiving. If you do decide to take part, we will, with your permission, let 
your G.P. know of your test results. This is standard practice in research and will not affect 
any care you receive from the NHS or your G.P. We will inform your G.P. of test results so 
that if you require any further assessment of your memory, these results can help inform the 
assessment. 
 
What does taking part involve? 
You will be invited to your nearest clinic or, if appropriate, the researcher can (with your 
permission) visit you at home. You will only need to attend the clinic (or receive a home visit) 
once. We are unfortunately unable to pay travel expenses. 
 
Taking part involves one short test which will assess your mental ability. You will also be 
asked for information about your age, gender, postcode and the number of years of 
education you have. The amount of time you can expect all this to take is approximately 15 
minutes.  
 
The researcher will also require access to previous ACE-III scores held within your medical 
records. 
 
What happens to the information? 
Your identity and personal information will be completely confidential and known only to the 
researcher, her academic supervisor (Professor Jonathan Evans) and representatives of the 
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study Sponsor, NHS Greater Glasgow & Clyde, who may look at it to make sure the study is 
being conducted correctly. The information obtained will remain confidential and stored 
within a locked filing cabinet and on a password protected computer. The data are held in 
accordance with the Data Protection Act, which means they are kept safely and cannot be 
revealed to other people, without your permission.  
 
What are the possible benefits of taking part? 
Many people find completing these sorts of tests interesting. It is hoped that by taking part 
you will be providing valuable information regarding how individuals aged 75 and over who 
are experiencing memory problems should score on the M-ACE. It is hoped that this 
information will influence further research into the use of short screening tools for detecting 
dementia. 
 
What are the possible disadvantages and risks of taking part? 
Your test results could indicate that your difficulties such as memory have become worse 
over time. In this instance, additional support can be provided by contacting your healthcare 
provider who may arrange a review or additional support measures for you. The researcher 
will be happy to help you with this if required. It will be helpful for your GP to be aware of the 
results of the tests and therefore if you give your permission we will inform your GP of your 
test results.  
 
If during the study, the researcher becomes aware that there are any risks of harm to 
yourself or other people, she will be duty-bound to pass this information on to relevant 
services, such as social work who may wish to speak with you further about this. Such risks 
include things like physical abuse and neglect. The researcher would, wherever possible, 
discuss this with you first, however would still need to pass the information on. This is 
standard practice and is designed to ensure that you and others are safe and are receiving 
the right amount of support and care.  
 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given 
favourable opinion by the NHS West of Scotland Research Ethics Committee, Greater 
Glasgow and Clyde Research and Development Department and the University of Glasgow. 
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What will happen to the results of the study? 
If you would like to know of the overall results and conclusions of the study, the researcher 
can provide this information to you upon completion of the study.  
 
If you have any further questions? 
You will have a copy of the information sheet and signed consent form to keep. 
If you would like any general information about participating in research within the NHS, 
please contact: 
 
Professor Tom McMillan 
Director of Research and Professor of Clinical Neuropsychology 
Room 213 Level 2 
Mental Health and Wellbeing 
Gartnaval Royal Hospital 
Glasgow G12 0XH 
Telephone: 0141 211 0354 
 
If you would like further information about this particular research project please contact 
Claire McGuire, her academic supervisor Professor Jonathan Evans or her clinical 
supervisor Dr Stephanie Crawford: 
 
Contacts: 
Miss. Claire McGuire 
Trainee Clinical Psychologist 
Gartnavel Royal Hospital 
1055 Great Western Road 
G12 0XH 
Tel: 0141 211 3920 
 
Professor Jonathan Evans 
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Professor of Applied Neuropsychology 
Gartnavel Royal Hospital 
1055 Great Western Road 
G12 0XH 
Tel: 0141 211 3978 
 
Dr Stephanie Crawford 
Clinical Psychologist 
Belmont Centre 
Stobhill Hospital 
300 Balgrayhill Road 
G21 3UR 
Tel: 0141 232 6660 
 
If you have a complaint about any aspect of the study? 
If you are unhappy about any aspect of the study and wish to make a complaint, please 
contact the researcher in the first instance. The normal NHS complaint mechanisms are also 
available to you. For information on our complaints procedures or advice on how to make a 
complaint: 
 phone: 0141 201 4500 (for complaints only) 
 email: complaints@ggc.scot.nhs.uk 
 
Thank you for your time  
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Appendix 2.12: Opt-in/Opt-out letter for people with an MCI 
       
An Investigation of the Utility of the Mini Addenbrooke’s Cognitive 
Examination (M-ACE) for the Early Detection of Dementia and Mild Cognitive 
Impairment in People Aged 75 and Over 
 
My name is Claire McGuire and I am a trainee Clinical Psychologist. I would like to invite you 
to take part in a research study which is exploring whether a short test is able to accurately 
predict if a person is experiencing problems with their mental ability which may be 
associated with the early stages of dementia. 
The study aims to explore these tests with people who have a dementia or mild cognitive 
impairment and with people who do not. All participants will be adults aged 75+. 
Taking part involves short tests of attention, memory and language which will take 
approximately 5-10 minutes in total. You will be invited to your nearest clinic or, if 
appropriate, the researcher can (with your permission) visit you at home. You will only need 
to attend the clinic (or receive a home visit) once. 
It is hoped that this information will influence how NHS staff use different tests and 
information to predict a person’s general functioning when assessing someone who has 
concerns about their memory. 
Your clinician will contact you about this study within the next few days. If you would 
like to indicate that you wish to take part or that you do not wish to take part please 
complete the opt-in/opt-out slip below and send to your clinician. 
------------------------------------------------------------------------------------------------------- 
An Investigation of the Utility of the Mini Addenbrooke’s Cognitive 
Examination (M-ACE) for the Early Detection of Dementia and Mild Cognitive 
Impairment in People Aged 75 and Over 
 
I wish/do not wish to be contacted regarding the above named study. 
Name: ________________________________________________________ 
Address: ______________________________________________________ 
______________________________________________________________ 
Telephone number: ______________________________________________ 
